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SUMMARY
There have been continual changes in medical diagnosis and treatment throughout the 
generations. Present medical practice emphasises accuracy and accountability, and an 
evidence base for diagnosis and therapeutic intervention. The differential diagnosis of 
tremor disorders and parkinsonism serves as a good example of evolving concepts and 
treatment approaches, and is the subject of the present thesis.
It is necessary first to review present knowledge about the accuracy of diagnosis and 
why this is important (Chapter 1), then to review how imaging techniques have 
contributed to the knowledge base (Chapter 2) and then report current understanding 
of the dopamine transporter (Chapter 3) - as it is at this site that the new isotope -123I- 
N-fluoropropyl-2p-carbomethoxy-3p-(4-iodophenyl) nortropane (123I-FP-CIT) is 
known to work.
It is the aim of the present thesis to examine an advanced phase of clinical application 
of the technique of SPECT imaging with 123I-FP-CIT to the differential diagnosis of 
selected movement disorders as follows:
In study 1 (Chapter 4) the design and result of study of 220 subjects with idiopathic 
Parkinson’s disease (iPD), multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP), essential tremor (ET) and healthy volunteers are presented. A new 
technique of assessing 123I-FP-CIT SPECT by visual inspection was developed which 
proved to be useful in differentiating essential tremor from other parkinsonian 
syndromes. Semi-quantitative analysis showed limited usefulness of 123I-FP-CIT
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SPECT in differentiating iPD from atypical parkinsonism. This study provides 
evidence against significant association between iPD and ET.
Study 2 (Chapter 5) addressed the issue of the correlation of severity, staging and 
duration of parkinsonian features with 123I-FP-CIT striatal uptake in 41 patients with 
iPD. A positive correlation of striatal uptake was identified for these variables and for 
bradykinesia, but not for tremor suggesting that tremor could have an origin outwith 
the dopamine transporter system. The clinical lateralisation of parkinsonian signs was 
studied in relation to striatal uptake with the finding that clinical asymmetry in iPD 
was more marked than the degree of the asymmetry in 123I-FP-CIT uptake. The 
patterns of 123I-FP-CIT uptake in iPD, 8 MSA, 3 PSP and 6 healthy volunteers were 
reported, confirming that the posterior putamen is the most affected part in iPD and 
showing that there are limitations in attempting to differentiate parkinsonism subtypes 
using this technique.
In study 3 (Chapter 6) 10 patients with tremor and/or clinical features suggesting 
possible parkinsonism (but not fulfilling diagnostic criteria for either iPD or ET) were 
compared to 9 unilateral patients fulfilling diagnostic criteria for iPD and 6 healthy 
volunteers. Reduced 123I-FP-CIT striatal uptake was found bilateral in 7 tremor patient 
and all 9 of the unilateral iPD patients, confirming the presymptomatic phase of the 
illness not only in early parkinsonism cases but even in monosymptomatic cases who 
have yet to develop definitive clinical features. Of the 10 tremor cases, 3 showed 
striatal uptake values above the range established for iPD patients fulfilling clinical 
criteria, even although the duration of disease in the tremor patients was similar to that 
in definite iPD patients. Three of the 10 tremor patients showed normal striatal
uptake. This indicated the usefulness of this technique in demonstrating the 
nigrostriatal change at a very early stage of disease, helping to exclude or confirm the 
diagnosis of parkinsonism.
In study 4 (Chapter 7) the relationship between cerebrovascular disease and 
parkinsonism was studied. 123I-FP-CIT striatal uptake in 12 patients with vascular 
parkinsonism was compared to 6 healthy volunteers. Also an index case of isolated 
tremor related to ischaemic lesion was reported. A reduction in uptake was shown in 
all vascular parkinsonism patients except one. Two distinct patterns of dopaminergic 
loss, both of which differ from idiopathic Parkinson’s disease were identified, 
indicating that vascular lesions may disrupt the dopaminergic system to produce 
parkinsonian features.
In summary, a simple visual inspection of 123I-FP-CIT SPECT scans helps in 
differentiating parkinsonian syndromes from essential tremor and detecting changes in 
the dopaminergic system in patients with unilateral parkinsonism, even in patients not 
fulfilling diagnostic criteria for iPD. However there are limitations in using this 
technique in differentiating iPD from MSA or PSP. A reduction in striatal uptake was 
shown in vascular parkinsonism patients supporting a dopaminergic source of 
symptoms in this group. The correlation of disease staging, severity and duration with 
striatal 123I-FP-CIT uptake indicates the potential usefulness of SPECT in monitoring 
disease progression and the effects of putative neuroprotective therapy.
In conclusion, this new technique represents a significant advance in medical 
diagnosis of movement disorders. It is not a substitute for clinical assessment but
xxii
should be used in conjunction with it, to clarify diagnosis where there is uncertainty, 
and in particular when this has implications for patient care, such as in guiding about 
prognosis, or in choosing drug treatments. As we enter the next century of medical 
innovation, it seems probable that this technique has future application as objective 
test for assessing the benefits of neuroprotective drugs, the effects of neuronal growth 
factors or the survival of transplant of dopaminergic material.
CHAPTER 1 
CLINICAL DIA GNOSTIC A CCURA CY OF
PARKINSONISM AND TREMOR DISORDERS:
PROBLEMS AND PITFALLS
i
1.1 DIAGNOSIS OF TREMOR AND PARKINSONISM
Accurate diagnosis of idiopathic Parkinson’s disease (iPD) is important in patient care 
through providing accurate prognostic information. The obvious differences in 
clinical progress and survival from the more benign essential tremor (ET) through the 
tremor dominant Parkinson’s disease to iPD itself and the Parkinson plus disorders, 
are reflected for example in survival statistics for Multiple System Atrophy (MSA) at 
6 years (Wenning et al 1997) and near normal life expectancy in iPD (Marsden 1994). 
It is appropriate for practising clinician to address patient and family concerns about 
prognosis from a firm diagnostic footing.
In drug treatment, accurate diagnosis allows for introduction and amendment of drug 
therapy tailored to the patient condition and clinical progress. For example patients 
initially diagnosed iPD in whom a revised diagnosis of ET or MSA is reached, can 
have appropriate levodopa withdrawal or adjustment. In addition, it is important to 
define an accurate patient cohort for clinical research studies, such as trials of putative 
neuroprotective drugs, or novel therapies for MSA and Progressive Supranuclear 
Palsy (PSP). Finally, accurate diagnosis would help in understanding the aetiology 
and pathophysiology of different causes of parkinsonism and tremor disorders, for 
example, similarities and differences between ET and benign tremulous Parkinson’s 
disease.
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1.2 PARKINSONISM
“Involuntary tremulous motion, with lessened muscular power, in parts not in 
action and even when supported; with a propensity to bend the trunk forward, and 
to pass from a walking to a running pace: the sense and intellects being uninjured. ”
James Parkinson 1817
Dr. James Parkinson, in his Essay on the Shaking Palsy, described six male patients 
aged 50 to 72 whose disease has since carried his name. It is interesting that no female 
patients were described. With great success, he illustrated in 66 pages and five 
chapters the features of Paralysis Agitans.
Parkinson described many cardinal features of the disorder: tremor “the shaking of the 
limbs...was particularly noticed”, onset and progress “symptoms gradually increase in 
the part affected ... seldom in less than twelve months or more, the morbid influence 
is felt in other part”, posture “patient is found to be less strict than usual in preserving 
an upright posture”, gait “irresistibly impelled to take much quicker and shorter steps, 
and thereby to adopt unwillingly a running pace”. He also mentioned other features of 
the disease such as, speech changes “words are now scarcely intelligible...the power 
of articulation is lost”, difficulty swallowing “the power of conveying the food to the 
mouth is at length”, sialorrhoea “saliva...is continually draining from the mouth”.
As for differential diagnosis, Parkinson recognised other causes of tremor such as 
alcohol, and “palsy as consequent to compression of the brain, or dependent on partial 
exhaustion of the energy of that organ”. He disagreed with the use of the term shaking
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palsy in convulsion and involuntary movement when he described two patients, one 
with ballistic attacks and another with possible torsion dystonia (Pearce 1989).
Parkinson mistakenly believed the site of pathological change to be in the superior 
cervical vertebrae and extending, as the disease proceeds, to the medulla oblongata. 
Although he expresses uncertainty he assumed that the disease could be a “result of 
injuries of the medulla itself, or of the theca helping to form the canal in which it is 
enclosed ”. However he makes it clear that no patient recollected receiving any injury. 
Without adequate knowledge of either the correct anatomical site or the nature of the 
chemical deficiencies, Parkinson made inappropriate suggestions for treatment such 
as “blood should be taken from the upper part of the neck, and purulent discharge 
obtained by appropriate use of the sabine Liniment”.
Parkinson ignored rigidity completely as a cardinal feature of the disease and it was 
described later by Trousseau’s 15th Lecture on Clinical Medicine (Pearce 1989). 
Also, Parkinson made some observations which were later proven to be untrue, such 
as “intellects being uninjured, and the tremulous motion of the limbs occur during 
sleep”. It is known now that dementia may occur in up to 44% of patients with iPD 
(Hughes et al 1993), and the tremor usually disappears in sleep.
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1.3 DEFINITION AND CLASSIFICATION OF PARKINSONISM
Parkinsonism is a clinical syndrome characterised by bradykinesia: slowness of 
movement, hypokinesia: reduced movement, akinesia: loss of movement, rigidity: 
increased resistance to passive extension and flexion, tremor: mainly resting and 
postural abnormalities.
Parkinsonism is usually classified as:
1. Idiopathic Parkinson’s disease, of unknown aetiology.
2. Parkinsonism as part of other neurodegenerative disorders.
3. Symptomatic (secondary) parkinsonism with known aetiology.
1.4 IDIOPATHIC PARKINSON’S DISEASE fiPDl
Idiopathic Parkinson’s Disease consists of parkinsonism and is characterised 
pathologically by changes of neuronal loss, with Lewy bodies, in the substantia nigra.
Lewy bodies, first described by German pathologist F H Lewy in 1914, are 
eosinophilic intracytoplasmic inclusions. These bodies are also found in specific 
extranigral sites in iPD, e.g. Locus coeruleus, thalamus, cerebral cortex and 
autonomic nervous system (Gibb 1989a). Lewy bodies are not specific for iPD, and 
are reported in elderly patients without clinical features of iPD, hence the term 
incidental Lewy bodies, which probably represent pre-clinical or early stages of iPD 
rather than the effect of age (Fomo 1969, Gibb and Lees 1988). Also, Lewy bodies 
are reported in MSA (Gibb 1988), PSP (Gomori et al 1984, Jellinger et al 1980), 
familial Alzheimer’s disease (Gibb et al 1989b), Hallervorden-Spatz disease (Gibb 
1989a), ataxia-telangiectasia (Agamonolis et al 1979), subacute sclerosing
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panencephalitis (Gibb et al 1990a), and diffuse Lewy body dementia (Gibb et al
1985). Other pathological changes such as Alzheimer-type pathology and vascular 
striatal abnormalities can coexist with the typical pathological features of iPD 
(Hughes et al 1992).
1.4.1 Epidemiology
Idiopathic Parkinson’s Disease is the commonest cause of parkinsonism (Quinn 
1995), with an annual incidence of 20.5 per 100 000 of the population and prevalence 
164 per 100 000 (Rajput et al 1984a, Mutch et al 1986). The prevalence of the disease 
increases with age from 47 per 100 000 for ages 40-49 years, to 832 per 100 000 for 
70-79 years (Mutch et al 1986).
In a population of 250 000 there are 400 patients with Parkinson’s Disease, of whom 
342 have significant disability (Association of British Neurologists 1992).
Therefore, iPD is a common and disabling condition particularly with increased age.
1.4.2 The Clinical Features and Course o f Idiopathic Parkinson’s Disease
The mean age at onset of iPD is between 55 and 65 years, with a slight male 
predominance of 60%, and mean age of death is 75.5 years (Hoehn and Yahr 1967, 
Mutch et al 1986, Hughes et al 1993). There is no difference in the age of onset, age 
at death or duration of illness between males and females (Hughes et al 1993).
In a study of clinical features of 100 pathologically proven cases of iPD, Hughes et al 
(1993) reported asymmetric disease onset in 72%. Marked tremor was present in 69%
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but 42% had tremor only without bradykinesia or rigidity. The disease was tremor 
dominant in 11%, akinetic rigid in 23%, and mixed in 64% with the mean survival 
being longer by 3.7 years in patients with tremor dominant disease. The initial 
response to levodopa was nil to poor in 6%, moderate in 17%, good in 53%, and 
excellent in 24%. Dementia was present in 44% of cases, increasing with duration of 
illness. Autonomic dysfunction was reported in 27 patients, mainly mild postural 
hypotension, although 4 patients had severe autonomic failure. Marked speech 
abnormalities were reported in 20, 11 patients had swallowing difficulties, and 13 had 
marked gait freezing. Over one quarter of iPD patients were dead or disabled within 5 
years, rising to 60% after 5-9 years, to over 80% after 10 to 14 years, and to almost 
90% after 15 years (Hoehn and Yahr 1967).
With the introduction of levodopa in 1968, mortality fell to approach that of the 
normal population (Marsden 1994). Ischaemic heart disease, cancer and 
cerebrovascular disease are the common causes of death unrelated to parkinsonism, 
while infections (broncho-pneumonia, urinary infection, infected bed sores), 
operations and accidents remain implicated in mortality related to parkinsonism 
(Hoehn and Yahr 1967, Hughes et al 1993). Survival had no relation to the type of 
onset or initial response to levodopa but correlated negatively to age at onset (Hughes 
et al 1993).
1.4,3 Diagnosis
The diagnosis of iPD can be very difficult especially in the early stage of the disease. 
There are no biological markers or specific neuroimaging techniques to diagnose this 
condition.
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Two major clinico-pathological studies have evaluated the accuracy of clinical 
diagnosis of iPD.
Hughes et al (1992) examined 100 consecutive cases with a clinical diagnosis of iPD 
over 3 years, of which 70 cases were assessed prospectively and annually by a 
neurologist associated with The Parkinson’s Disease Society Brain Bank, and other 
cases were diagnosed by consultant neurologists or geriatricians.
Pathologically, the diagnosis was based on finding a clear depletion of brain stem 
pigmented neurones with the presence of Lewy bodies in some of the remaining nerve 
cells. Of the 100 cases, 76 fulfilled pathological criteria, while the remaining 24 
patients were clinically misdiagnosed. The principle findings in the cases without 
Lewy bodies were PSP (six), MSA (five), Alzheimer’s disease (three), Alzheimer- 
type pathology (three), vascular disease (three), isolated nigral atrophy with no Lewy 
bodies (two), post-encephalitic parkinsonism (one), and one case with normal 
pathology in which review of the clinical details suggested possible ET. Retrospective 
application of the UK Brain Bank Criteria improved the diagnostic accuracy to 82%. 
Three patients with atypical clinical features had typical pathological features of iPD.
In a similar clinico-pathological study, 59 patients with parkinsonism had postmortem 
examination (Rajput et al 1991a). The initial diagnosis was iPD in 43 patients, in 
whom Lewy body pathology was verified in only 28 (65%). The final clinical 
diagnosis after an average duration of illness of 11.7 years (range 2-39) was iPD in 41 
patients (76%). The diagnosis in the 10 cases who were incorrectly labelled as iPD 
were: striatonigral degeneration (four), profound substantia nigra neuronal loss
without inclusions (two), neurofibrillary tangle parkinsonism (two), drug induced 
parkinsonism (one), and Alzheimer’s disease (one).
Both of these pathological studies indicate that 24% of patients with a clinical 
diagnosis of iPD do not fulfil pathological criteria and have an alternative diagnosis. 
MSA or PSP are the most common pathological diagnoses in such cases.
The bias introduced by pathological studies when compared to a clinical setting, is in 
the absence of the most common movement disorder ET. The presence of only one 
case within the above two clinico-pathological studies probably reflects the benign 
course of ET.
Also, applying rigid clinical criteria could lead to misdiagnosis. In a study of 100 
pathologically proven iPD patients, 12 cases failed to fulfil the UK Brain Bank 
Criteria. Thus patients with unusual features, such as early onset of dementia or poor 
response to levodopa, may still have iPD (Hughes et al 1993).
1.5 MULTIPLE SYSTEM ATROPHY (MSAl
MSA is a sporadic, adult onset, neurodegenerative disease. It is a clinico-pathological 
entity which can be present with any combination of parkinsonism, cerebellar and/or 
pyramidal signs and autonomic dysfunction.
Pathologically, it is characterised by cell loss and gliosis in any two of the following 
brain areas: substantia nigra, striatum, locus coeruleus, pontine nuclei, cerebellar
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purkinje cells, inferior olives, together with the presence of oligodendroglial 
cytoplasmic inclusions (Quinn 1994, Wenning et al 1995).
1.5.1 Classification
Shy and Drager described in 1960 a neurological syndrome associated with 
orthostatic hypotension. In 1969, Graham and Oppenheimer introduced the term 
MSA, but it has since become a title which covers a wide range of different 
degenerative conditions (Quinn 1994).
There is ongoing debate about how to use these terms. The following subtypes of 
MSA have been defined in a clinico-pathological study (Litvan et al 1997):
(i) Shy-Drager syndrome, in which autonomic failure predominates.
(ii) Striatonigral degeneration, in which parkinsonism predominates.
(iii) Olivopontocerebellar atrophy, in which cerebellar features predominate.
However, Oertel and Quinn (1996) argue against using the term Shy-Drager 
syndrome because autonomic dysfunction is almost universal in MSA (Wenning et al 
1994a) and they defined MSA subtypes as follows:
(i) Striatonigral degeneration (MSA - parkinsonian type).
(ii) Sporadic olivopontocerebellar atrophy (MSA - cerebellar type).
Wenning et al (1995) further emphasised the overlap in clinical features in a clinico- 
pathological study of 35 cases of MSA, in which one case had isolated parkinsonism 
and the remaining 34 had a mixture of autonomic, cerebellar and pyramidal features at 
different times through the clinical course.
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1.5.2 Epidemiology
MSA contributes to between 3.6 and 22% of incident cases of parkinsonism, a mean 
figure of 8.2%. The wide range indicates the need for a prospective population-based 
study of this condition, with pathological follow-up (Quinn 1994, Wenning et al 
1997).
1.5.3 Clinical Features
Wenning et al (1997) reviewed the clinico-pathological features of 203 cases, from 
the literature, with pathologically proven MSA. The male: female ratio was 1.3:1 with 
mean age of onset 54.3 years, mean age at death was 60.3 years and mean duration of 
illness was 6.1 years. Bronchopneumonia was the most common cause of death. Pure 
striatonigral degeneration (SND) was present in 46%, predominantly SND in 14%, 
pure olivopontocerebellar atrophy (OPCA) in 13%, predominantly OPCA in 15%, and 
12% had an equal mix of parkinsonism and cerebellar features.
Autonomic features were present in 74% of the cases with urinary incontinence in 
55% and/or urinary retention in 18%. Impotence was reported in 47% of male 
patients. Postural faintness was present in 51%.
Parkinsonism occurred in 87% of cases, all of them had akinesia, and two thirds had 
rigidity or tremor, rest tremor was described in 39% and classical pill-rolling rest 
tremor seen only 8% of patients.
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Cerebellar signs, mainly gait ataxia, were present in 54% and pyramidal signs in 48%, 
41% showed extensor plantars while 46% showed hyperreflexia and only 10% of 
patients had spastic paraparesis.
Other features included stridor (13%), intellectual deterioration which was mild in 
22%, moderate in 2%, and severe in 0.5%.
Only 28% of patients had a good or excellent response to levodopa while 27% 
developed dyskinesia, mainly axial.
In a clinical series of 100 consecutive patients with a clinical diagnosis of probable 
MSA, Wenning et al (1994a) showed similar prevalence rates of parkinsonism, 
cerebellar ataxia, and pyramidal features. Autonomic failure however, was reported 
more in the clinical series, probably because of reporting bias in favour of more 
severe autonomic features and in favour of motor features. Also, the median survival 
in the clinical series was 9.5 years suggesting either more severe cases in the 
published postmortem series, or less diagnostic accuracy in the clinical series.
These studies showed clearly the clinical features, the worse prognosis for MSA than 
iPD, and the poor response to anti-parkinsonian medication.
Litvan et al (1997) addressed the issue of the accuracy of clinical diagnosis of MSA 
by studying 105 autopsy cases of parkinsonism, and found MSA in 16 cases, and 
related disorders in 89 cases. Neurologists correctly identified 25% of the 16 MSA 
cases at the first clinic visit (a median of 42 months after the onset of symptoms) and
12
50% at the last visit (74 months after the onset of symptoms). In another study only 
29% of patients shown to have MSA had the correct clinical diagnosis at the time of 
death (Wenning et al 1997). Clearly therefore, MSA is under-recognized, and is 
frequently misdiagnosed as either iPD or PSP. Early severe autonomic failure, 
absence of cognitive impairment, early cerebellar symptoms, and early gait 
disturbances were identified as the best predictive features to diagnose MSA.
1.6 PROGRESSIVE SUPRANUCLEAR PALSY (PSP!
(STEELE-RICH ARDSON-OLSZWESKI SYNDROME!
Steele, Richardson and Olszewski (1964) described clinical and pathological features 
of nine patients with a progressive disorder of vertical gaze, axial rigidity, dysarthria, 
pseudobulbar palsy and mild dementia, which they called Progressive Supranuclear 
Palsy.
1.6.1 Epidemiology
PSP is under-diagnosed, making accurate epidemiological data difficult to obtain. 
However, from a search of neurologists, nursing homes and movement disorder centre 
records in New Jersey with a total population of 800 000, a prevalence of 1.46 per 
100 000 and annual incidence of 3.1 to 4.0 cases per million has been estimated 
(Golbe et al 1988).
Although all of the initial reported cases were male (Steele et al 1964), no significant 
sex difference (Golbe et al 1988), or only a slight (1.5:1) male predominance (Lees et 
al 1987) are now recognised. Three necropsy series have also confirmed this (De 
Bruin et al 1994, Collins et al 1995a, Litvan et al 1996a).
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1.6.2 Clinical Features
PSP is a sporadic disorder, but familial cases have been described (Brown et al 1993, 
de Yebenes et al 1995). Patients with PSP usually present in the seventh decade, with 
postural instability and falls in the first year in more than 50% and dysarthria in one 
third. Visual disturbances in form of diplopia, blurred vision, burning eyes, and light 
sensitivity are the initial symptoms in around 15% of patients. Cognitive or 
behavioural changes generally follow (Litvan et al 1996a).
Vertical downward gaze palsy is the single most important clinical feature of PSP. 
Although upward gaze and convergence become impaired first, this also occurs in 
other basal ganglia disorders and in old age (Lees 1987). The oculocephalic 
manoeuvre remains intact (except in very advanced stages), and it is this characteristic 
that makes the disorder supranuclear (Jankovic 1984, Stell and Bronstein 1994). Other 
ocular manifestations include supranuclear ophthalmoplegia, absent Bell’s 
phenomenon, impaired pupillary light reflexes, lid retraction, a markedly reduced 
blink rate, frontalis muscle over-activity, blepharospasm, and apraxia of eye opening 
or closure (Duvoisin et al 1987, Lees 1987). These changes give the patient a fixed, 
staring, and astonished expression (Lees 1987). Although the presence of down-gaze 
palsy is an essential finding to secure the diagnosis of PSP, there are a few 
pathologically proven cases reported which did not develop such abnormality during 
life (Collins et al 1995a, Litvan et al 1996a). Other clinical features include; bilateral 
bradykinesia, axial rigidity, speech changes (dysphonia, palilalia, ataxic and 
unintelligible speech), frontal lobe symptoms, personality changes, dysphagia and 
neck dystonia (Litvan et al 1996a).
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I In a review of first and last neurology clinical visits of 24 patients with pathologically 
confirmed PSP to tertiary centres in three European countries and USA, the first clinic 
visit occurred at a mean of 3.7 years after the onset of symptoms. Most of the patients 
had gait disorder, postural instability, backward falls, bilateral bradykinesia, axial 
rigidity, vertical supranuclear palsy, and dysarthria. The median survival from the 
onset of the disease was 5.6 years and the most common cause of death was 
pneumonia. The clinical diagnosis by the attending Neurologist was correct in 58% of 
PSP cases at the first visit, while an incorrect diagnosis of iPD was made in 21%. 
Recognition of an atypical parkinsonism was made in some cases, but with the wrong 
label applied: corticobasal degeneration in 4%, Alzheimer’s disease in 4% and others 
in 8%. The diagnostic accuracy improved to 88% at the final visit pre-mortem, 
indicating that PSP is under-diagnosed especially in the early course of the disease 
(Litvan et al 1996a).
1.6.3 Pathology
Pathological criteria of typical PSP are of a high density (two or more neurones) of 
neurofibrillary tangles and neuropil threads in at least three of the following areas: 
pallidum, subthalamic nucleus, substantia nigra, and pons, and a low (one or more 
neurone) to high density in at least three of the following areas: striatum, oculomotor 
complex, medulla, and dentate nucleus. The presence of tau-positive astrocytes or 
processes or tangles in astrocytes in these areas also supports the diagnosis. Atypical 
PSP should be diagnosed if the pathological finding are a low density of 
neurofibrillary tangles and neuropil threads in at least five of the following areas: 
pallidum, subthalamic nucleus, substantia nigra, pons, medulla, and dentate nucleus 
(Hauw et al 1994).
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I 1.7 RED FLAGS
!
| Quinn (1995) has described a number of clinical features (red flags) which should
alert the clinicians to the possibility of an atypical parkinsonian disorder. The most 
important are, absent or poor response to levodopa, rapid disease progression, 
autonomic failure, early falls, cerebellar and/or pyramidal signs, supranuclear palsy, 
lower body parkinsonism, early dementia, and early or severe speech and swallowing 
impairment.
1.8 ESSENTIAL TREMOR (ET1
1.8.1 Definition and Classification
Essential Tremor is a tremor typically on posture and therefore occurring while 
voluntarily maintaining position against gravity and mainly involving the upper limbs. 
It is different from parkinsonian tremor which is mainly resting and therefore occurs 
inactive muscles which are completely supported against gravity (Findley and Koller 
1995, Findley 1996).
1.8.2 Diagn ostic Difficulties
Although the description of tremor in parkinsonism and ET implies clear separation of 
the tremor types, there is often a degree of overlap (Martinelli et al 1987), and 
therefore Findley (1996) states that “no single type of tremor can be pathognomonic 
of a particular disorder”.
Essential tremor may be misdiagnosed as iPD. Hoehn and Yahr (1967) reviewed 856 
patients with a diagnosis of parkinsonism and 39 were found to have ET. Critchley 
(1972) reviewed 42 patients with ET and found 10% incorrectly diagnosed as 
parkinsonism. Larsen and Caine (1983) have stated that “patients with essential
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tremor are commonly diagnosed as having Parkinson’s disease..., the frequency of 
this mistake has varied from 20% to 25%”. Quinn (1995) acknowledges that essential 
tremor is one of the two conditions most commonly misdiagnosed as iPD by many 
non-specialists, and even by some specialists. Recently, 402 cases with presumed iPD 
receiving antiparkinsonian medication were reviewed in a community-based study, 
and 50 patients (29%) were found to have ET without any features of parkinsonism 
(Meara et al 1999).
1.8.3 Epidemiology
Essential tremor is the commonest movement disorder, with a prevalence rate up to 20 
times that of iPD, although only 10% of patients aged above 40 have sought medical 
treatment (Rautakorpi et al 1982).
The world-wide prevalence is estimated at between 4 and 39 per 1000, and increases 
up to 50 per 1000 with advancing age (Louis et al 1998). The annual incidence is 
about 23 per 100 000 population (Rajput et al 1984b).
1.8.4 Clinical Features
A bimodal distribution with peaks in the second and fifth decades has been reported 
with men and women equally affected (Lou and Jankovic 1991, Bain et al 1994), but 
other studies indicate an onset usually around 45 years with an earlier onset in familial 
ET (Koller et al 1994). No correlation has been found between the age of onset and 
either tremor severity or disability, but both severity and disability increase with 
advancing age and tremor duration (Bain et al 1994).
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Although ET may be classified as either hereditary or sporadic, clinical features are 
usually discussed without distinguishing between the two based on the assumption 
that they are the same entity (Bain 1993).
The main manifestation of ET is postural and/or kinetic tremor of the hands, starting 
intermittently and progressing to become permanent, rarely remitting (Larsen and 
Caine 1983) and usually worsened by emotion. Tremor of the head, voice, tongue, 
and legs may follow (Lou and Jankovic 1991, Bain et al 1994).
Essential tremor is sometimes described as benign, and although it does not affect life 
expectancy, it can impair physical function, such as the ability to eat, drink, write and 
can be a social embarrassment (Koller et al 1986, Busenbark et al 1991). Up to 15% 
of patients took early retirement as a result of the disability caused by the tremor 
(Rautakorpi et al 1982).
There are no specific pathological features of ET (Rajput et al 1991b).
1.8.5 How Familial is Essential Tremor?
It is commonly stated that 30 to 50% of ET patients have an affected relative 
(Martinelli et al 1987, Salemi et al 1994). In reviewing all service-based and 
community-based published studies of familial aggregation in ET, Louis et al (1996) 
found a range of 17-100% for reporting of affected relatives, clearly suggesting 
variation in data collection techniques. Busenbark et al (1996) found on an initial 
assessment 67% of patients reported a positive family history but after full 
assessments including a mailed questionnaire to all first degree relatives this was
18
increased to 96%. Penetrance is usually complete by the age of 65 years, and no 
evidence of the disease skipping a generation was found in studying 20 kindreds, 
thereby indicating autosomal dominant inheritance (Bain et al 1994). However no 
responsible gene has yet been identified (Britton 1995).
1.8.6 Effect o f  Alcohol
As many as 50-66% of ET patients report improvement of their tremor after alcohol 
(Critchley M 1949, Critchley E 1972, Lou and Jankovic al 1991, Bain et al 1994). 
Although this was reported for postural tremor associated with parkinsonism (Rajput 
et al 1975), Koller and Biary (1984) found no effect of intravenous ethanol in 5 iPD 
patients with resting tremor compared to 15 ET patients.
The rate of alcoholism in ET patients was reported to be high in one retrospective 
study (Schroeder and Nasrallah 1982), but another prospective study did not confirm 
this (Koller 1983).
1.9 VASCULAR PARKINSONISM (VP)
Stroke is much more common than iPD, especially among the elderly population, with 
an overall incidence of 200 per 100 000 increasing to 1400 per 100 000 for a 
population aged 75-84 years and an overall prevalence of 800 per 100 000 in the UK 
(Bamford et al 1988, Warlow 1991). The annual incidence of iPD is 20.5 per 100 000 
of the population and the prevalence 164 per 100 000 (Rajput et al 1984a, Mutch et al
1986). The prevalence of the disease increases with age from 47 per 100 000 for ages 
40-49 years, to 832 per 100 000 for 70-79 years (Mutch et al 1986). Therefore, there 
is an overall 1.6 per 100 000 chance for case of iPD to have co-existing
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cerebrovascular disease, while increases to 11 per 100 000 for patients aged over 70 
years.
Alternatively, a parkinsonian syndrome may be caused by cerebrovascular disease, a 
concept introduced when Critchley (1929) described 5 types of clinical presentation 
of what he termed arteriosclerotic parkinsonism. Rigidity, fixed faces and short- 
stepping gait were the main clinical signs. Pseudo-bulbar, dementia, incontinence, 
pyramidal or cerebellar signs were considered as additional features. After several 
clinical studies in the 1960’s and 1970’s showed no relation between arteriosclerosis 
and iPD (Eadie et al 1964, Parkes et al 1974, Marttila et al 1976b), Critchley in 1981 
renamed the condition arteriosclerotic pseudo-parkinsonism. Several alternative terms 
have been used including vascular parkinsonism and lower body parkinsonism, but 
there are no generally accepted clinical criteria to diagnose the condition.
With the development of CT and MRI the concept of vascular parkinsonism was 
revived (Chang et al 1992, Inznelberg et al 1994, Reider-Groswasser et al 1995). This 
was supported by postmortem studies showing that iPD can co-exist with vascular 
lesions in the striatum, and lacunar infarcts can produce clinical features similar in all 
aspects to iPD including a response to levodopa (Tolosa and Santamaria 1984, 
Murrow et al 1990, Hughes et al 1991, 1992).
Several clinical features have been described relating brain vascular lesions to 
parkinsonism. Two patients presented with acute onset parkinsonism, due to vascular 
lesions in the basal ganglia, and recovery without anti-parkinsonian drugs had been 
reported (Friedman et al 1986, Mayo et al 1986). On the other hand, an insidious
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| onset of parkinsonism at times indistinguishable from iPD due to brain vascular
I
; infarcts has been described (Tolosa and Santamaria 1984, Murrow et al 1990,
Inzelberg et al 1994, Reider-Groswasser et al 1995, Mark et al 1995).
Lower body parkinsonism (LBP) is another clinical pattern suggesting a 
cerebrovascular cause for parkinsonian features. FitzGerald and Jankovic (1989) 
compared ten patients with marked gait difficulty to 100 patients with iPD. Gait 
disturbance was the initial symptom in 7% of iPD cases. The only difference in 
vascular risk factors was an excess of hypertension in LBP. Only 22% of LBP 
responded to levodopa while 96% of iPD responded. Scores for speech, hypomimia, 
neck rigidity, and upper limb rest tremor, rigidity, and hand dexterity were 
significantly lower in LBP emphasising the relative sparing, though not absence, of 
the upper body and trunk involvement. The duration of symptoms was considerably 
shorter in LBP than iPD. All LBP patients had structural imaging (MRI, CT, or both) 
performed, and multiple deep sub-cortical lesions were seen in all but one. On the 
other hand only 4 of 8 MRI scans and one of 34 CTs for patients with iPD showed 
sub-cortical white matter lesions. In a clinico-pathologic study Yamanouchi and 
Nagura (1997) compared the symptoms and signs in 24 patients with VP (defined as: 
parkinsonism with evidence of cerebrovascular lesions and no depigmentation or 
Lewy bodies in the substantia nigra) with 30 age-matched pathologically confirmed 
iPD patients. Also, they compared the brain pathological changes in VP patients with 
22 age-matched Binswanger’s disease cases without parkinsonism. Resting tremor 
was present in one patients, and action tremor in 3 patients with VP while 22 patients 
with iPD had tremor. Nine patients with VP had hemiparesis and 15 had pyramidal 
signs, while no hemiparesis or pyramidal signs were found in iPD. Half of the patients
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with VP had pseudobulbar palsy, and 27% of iPD patients had dysphagia or 
dysarthria. Dementia was present in 17 VP and 13 iPD cases. Fifteen VP patients 
received anti-parkinsonian medications, none showed good response, 3 a transient 
response, and the remaining 12 showed no response at all, while the majority of iPD 
patients showed a good response. Asymmetry of limb rigidity was reported in 7 
patients with VP and 22 iPD patients. Interestingly, no difference was found in the 
gait disorders between VP (all patients had gait problems) and iPD (23 patients). 
Pathologically, 11 iPD patients had evidence of cerebrovascular disease. The white 
matter lesions in VP were less severe than Binswanger’s disease but the extent of 
vascular lesions in both groups were equal.
Recently, Winikates and Jankovic (1999) reported a difference in the clinical features 
of vascular parkinsonism compared to iPD. They defined vascular parkinsonism as 
patients with at least 2 of the 4 cardinal features of parkinsonism (bradykinesia, 
rigidity, tremor and postural instability) and 2 or more points on a specially design 
vascular rating scale (2 points for pathologically or angiographically proven diffuse 
vascular disease, 1 point for onset of parkinsonism within 1 month of clinical stroke, 1 
point for history of 2 or more strokes, 1 point for history of 2 or more risk factors of 
stroke, and 1 point for neuroimaging evidence of vascular disease in 2 or more 
vascular territories). They found VP patients were older, more likely to present with 
gait difficulty rather than tremor, and less likely to respond to levodopa. Also VP 
patients tend to have more predominant lower body involvement, postural instability, 
a history of falling, dementia, corticospinal findings, incontinence and pseudobulbar 
palsy.
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Therefore, LBP or VP may represent a group of patients, probably hypertensive, who 
usually have gait difficulty, symmetrical rigidity, absent tremor, and no response to 
levodopa therapy.
The association of ischaemic stroke and vascular risk factors was addressed in two 
studies, where the incidence of ischaemic stroke among iPD patients was lower than 
controls in one study (Struck et al 1990) but an association was found in another 
(Levine et al 1992). Cigarette smoking is recognised as protective from iPD 
(Baumann et al 1980, Morens et al 1996) and a low incidence of both smoking and 
myocardial infarction has been shown in iPD patients (Struck et al 1990, Levine et al
1992).
Thus iPD may co-exist with cerebrovascular disease, but there may be a lower 
probability of a chance association because of the risk factor profiles for each disease. 
Postmortem studies provide definite evidence that iPD patients may also have 
cerebrovascular disease, and that patients with parkinsonism may have 
cerebrovascular disease but no pathological features of iPD (Hughes et al 1992). The 
clearest clinical description of parkinsonism in association with cerebrovascular 
disease is that of LBP. However, upper body signs and symptoms are not excluded in 
such patients, and a vascular aetiology for patients with less than pure lower body 
features appears possible. Finally, a small subset of patients may be unfortunate 
enough to have predominately upper body features from iPD and lower body features 
from VP.
23
i
1.10 DIAGNOSTIC CHALLENGE TESTS FOR PARKINSONISM
The concept of diagnostic challenge tests for patients with parkinsonism was 
introduced recently to assess the dopaminergic responsiveness in patients with 
parkinsonism.
Hughes et al (1990) performed apomorphine and levodopa challenge testing in 65 iPD 
patients (15 de novo, 16 stable and 34 fluctuators) and 35 parkinsonian syndrome (PS) 
patients (4 MSA, 6 PSP, 5 dementia with parkinsonism, 4 possible early iPD, 8 
Parkinson’s plus and 8 others). Motor function was assessed using alternate unilateral 
hand tapping for 30 seconds on digital counters mounted 20 cm apart, time taken to 
walk 12 metres, clinical assessments of tremor and dyskinesia according to a four- 
point scale, and modified Webster disability scale. A test was considered positive if 
there was a 15% or more increase in tapping score, a 25% or more improvement in 
walking time, reduction of tremor score alone of a least 2 points, or an improvement 
of Webster’s score of 3 or more. Long-term response to levodopa was also assessed. 
Fifty-one iPD and 7 PS patients showed a positive response to challenge testing and 
there were 6 false negative results in iPD cases and 2 in PS cases. There was only one 
questionable false positive in the iPD group. Challenge testing accurately predicted 
the long-term response to dopaminergic therapy in 90% of patients.
In another study of 20 iPD and 8 PS cases (5 MSA, and 3 PSP) apomorphine 
challenge testing was assessed by tapping and walking measures and considered 
positive if there was a 15% or more increase in either walking or tapping measures. 
The response to sustained levodopa treatment was assessed a month later. The 
majority of iPD patients (95%) and 25% of PS responded positively to challenge tests,
24
and there was one false positive in the iPD group, and two false positives and two 
false negatives in PS group. Again challenge testing accurately predicted the long­
term response to dopaminergic therapy in 90% of patients. (D’Costa et al 1991).
In untreated iPD, Hughes et al (1991) reported a predictive accuracy of only 67% for 
apomorphine and 80% for levodopa. There were 13 false negative and 2 false positive 
apomorphine tests and 7 false negative and 2 false positive levodopa tests. After 
prolonged follow-up, 10% of patients showed features atypical for iPD, which may 
explain the relatively low predictive accuracy. Another explanation is that some 
patients with early iPD may have very mild parkinsonian signs, making the 
assessment of improvement difficult. The discrepancy between apomorphine and 
levodopa results has been considered as due to dose-limiting side effects of 
apomorphine. In another study of 62 untreated iPD cases, apomorphine had a 
predictive accuracy of 81%, sensitivity of 90%, and specificity of 88%. Motor 
function was assessed in three ways, the impression of the investigator, finger tapping 
and the UPDRS motor section of which the UPDRS was the best predictor (Gasser et 
al 1992).
Although there are some limitations in challenge testing, it can help in assessing 
dopaminergic responsiveness and guide appropriate therapy either by dose escalation 
in responsive cases, or drug withdrawal in non-responders. Positive challenge testing 
makes iPD likely but may also be positive in cases of MSA and PSP.
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CHAPTER 2 
IMA GING IN PARKINSONIAN SYNDROMES
Imaging techniques are of obvious interest in the diagnosis of parkinsonism and 
tremor disorders. Structural cerebral imaging (CT and MRI) identifies some causes of 
secondary parkinsonism, such as infarction, haemorrhage, tumours and 
hydrocephalus, and shows certain distinguishing features of MSA, and PSP, although 
these are not of adequate sensitivity for clinical practice. Recent developments in 
functional neuroimaging (PET and SPECT) allowed a detailed in vivo study of 
dopaminergic system, with its pre- and post-synaptic structures, in normal human 
brain and in parkinsonian patients.
Prior studies of these different techniques are now reviewed.
2.1 COMPUTERISED TOMOGRAPHY (CT)
Brain atrophy is the main CT scan finding in PS. In a study of 173 iPD patients, 51% 
were considered to have pathological brain atrophy (Becker et al 1979). Steiner et al 
(1985) reported brain atrophy in younger patients with iPD, while one in three patients 
were reported to have preffontal atrophy mainly the older ones (Adam et al 1983). 
Brain stem atrophy is seen with PSP, usually more obvious in the later stage of the 
disease (Schonfeld et al 1987). In MSA Wenning et al (1994b) found 21% of 33 
patients with normal CT, 42% showed infratentorial atrophy, cerebellar atrophy was 
present in 39% and pontine atrophy in 18%, although these findings were not thought 
to be particularly helpful in making a diagnosis of MSA.
Thus, atrophy affecting various parts of the brain can be identified on CT scan in PS, 
however, it seldom helps in diagnosis or differentiation between iPD, MSA, or PSP.
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2.2 MAGNETIC RESONANCE IMAGING (MRP
Decreased signal intensity of the putamen compared to the globus pallidus, and
(
| decreased signal intensity of the lateral substantia nigra on T2 weighted MRI is 
reported in MSA and PSP (Drayer et al 1986, Pastakia et al 1986, Stem et al 1989, 
Olanow et al 1992). However not all PSP patients have signal hypointensity in the 
putamen. While iPD patients and controls have normal putamen signal (Olanow et al 
1987, Braffinan et al 1988). The MRI changes did not differentiate PSP, MSA and 
atypical parkinsonism cases (Stem et al 1989). The amount of putaminal atrophy but 
not the degree of putaminal hypointensity correlates with the severity of MSA (Wakai 
et al 1994). In a study of the usefulness of MRI in MSA, Schrag et al (1998) reported 
that putaminal atrophy, a hyperintense putaminal rim and infratentorial signal have a 
high specificity but low sensitivity, while finding any infratentorial abnormality is 
highly sensitive but has low specificity.
The width of the substantia nigra pars compacta was reduced in iPD compared with 
controls on T2-weighted MRI (Duguid et al 1986, Braffinan et al 1988). However, the 
reduction was found only in advanced and not early-stage iPD patients (Huber et al
1990). This narrowing of pars compacta was also found in MSA, PSP and atypical 
parkinsonism (Stem et al 1989). Olanow (1992) commented on variability, according 
to MRI protocols, with widths of 5.2±0.15 mm in one study and 0.68±0.09 mm in 
another, so comparison between studies is difficult.
Midbrain atrophy is another feature on MRI scanning in some patients with PSP, 
MSA, and atypical parkinsonism (Rutledge et al 1987, Stem et al 1989, Yagishita and 
Oda 1995). Also, a significant shortening of the T2 relaxation time was found in
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substantia nigra, caudate nucleus and putamen in iPD patients which is likely to be 
due to an increased iron concentration in these areas. However this feature was not a 
reliable measure to differentiate iPD patients from healthy controls (Antonini et al
1993). These changes increase in patients with more than a 10 year history of iPD 
(Ryvlin et al 1995).
A signal change in the dorso-lateral aspect of the substantia nigra has been described 
in parkinsonism and is referred to as restoration, meaning that the normally reduced 
signal in this brain area was found to be replaced by a signal level similar to that of 
brain parenchyma without iron (Rutledge et al 1987). This finding was not confirmed 
in a later report (Braffinan et al 1988).
Thus the MRI changes in parkinsonism reflect focal atrophy which may give 
diagnostic clues, but these tend to be subtle or absent in early stages of the disease and 
are not practically useful in differentiating parkinsonism from other movement 
disorders or classifying parkinsonism.
2.3 FUNCTIONAL IMAGING
PET and SPECT are the two major types of functional neuroimaging. PET is not 
generally accessible to clinical practice due to the great expense involved in 
establishing a PET centre, while SPECT is less expensive and more easily available
QQ 19*3because the tracers used, ( mTc or I based) have a longer half-life. However, 
SPECT measurements are semi-quantitative, and provide less reconstructed resolution 
than PET, which is considered a disadvantage (Brooks 1993).
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2.4 PET STUDIES
2.4.1 [ISF] 2-Fluoro-2-Deoxy-Glucose PET (FDG PET)
FDG PET was used to measure regional cerebral glucose metabolism in several 
studies of patients with parkinsonism.
De Voider et al (1989) reported significant hypometabolism in the putamen, caudate 
and frontal cortex in 7 patients with probable SND when compared with 16 controls 
using FDG PET. When compared with severity and duration matched iPD, striatal 
metabolism was also significantly reduced. Putamen metabolism correlated with the 
severity of the disease measured by UPDRS motor scores in the SND patients but 
caudate metabolism did not show such a correlation (Eidelberg et al 1993). Otsuka et 
al (1991, 1996) reported reduced striatal glucose metabolism of patients with atypical 
parkinsonism and MSA when compared with iPD patients, however there was no 
difference in the striatal and cerebral glucose metabolism between iPD and controls. 
In another study of 9 MSA patients, 10 iPD and 10 healthy controls, caudate glucose 
metabolism measured by FDG PET was not able to differentiate between the three 
groups. On the other hand putamen metabolism was significantly reduced in MSA 
when compared with controls and iPD patients. Putamenxaudate ratio was also 
reduced in MSA patients when compared with the other two groups. Using 
discriminant function analysis, caudate and putamen FDG values differentiate 
between MSA and iPD patients, and separate MSA from controls but not between iPD 
from normal control. No correlation between putamen FDG values and MSA severity 
was found (Antonini et al 1997). Otsuki et al (1997) showed no difference in glucose 
metabolic rate in frontal, temporal, caudate, putamen, cerebellar, and brain stem areas 
in iPD and controls. However, the metabolic rate in these areas was significantly
30
reduced in MSA compared to controls and iPD patients only in caudate, putamen, 
cerebellar, and brain stem areas. In another study 75% of 48 patients with an atypical 
parkinsonian disorder showed striatal abnormalities when compared with 56 patients 
with iPD (Antonini et al 1998).
2.4.2 6-[18F] Fluoro-L-3, 4- Dihydroxyphenylalanine ( 8F-Dopa PET)
Uptake of 18F-dopa reflects the ability of the striatum to decarboxylate dopa because 
the striatum handles 18F-dopa, after an intravenous injection, in a similar way to 
endogenous dopamine (Brooks 1993).
Early studies of 18F-dopa PET in iPD showed bilateral reduction of putamen tracer 
uptake, with activity being most reduced in the putamen contralateral to the affected 
side in patients with hemiparkinsonism (Garnett et al 1984, Nahmias et al 1985). 
Leenders et al (1986) confirmed these findings and found that patients with long
1 ftstanding iPD retain F-dopa less effectively than those with early disease.
18F-dopa PET as a tool for differential diagnosis of PS and tremor disorders has been
1 ftused in various studies. In one such study, regional striatal F-dopa uptake was
depressed in 16 iPD patients compared to normal subjects but there was significant
sparing of the head of caudate and anterior putamen and severe involvement of the
posterior putamen. In 10 PSP patients a uniform severe depression of striatal 18F-dopa 
uptake in the caudate, anterior and posterior putamen was demonstrated while in 18
MSA patients the reduced uptake pattern appeared to be a mixture of the features seen
in iPD and PSP. The severity of disease assessed by the H&Y scale correlated with the
decline in lsF-dopa uptake in iPD and MSA, but not PSP patients (Brooks et al
1990). Bum et al (1994) reported that 18F-dopa PET, by using discriminant function
analysis, differentiated PS patients from controls, and also, between iPD and PSP
patients but not between iPD and MSA. However, no differences were found in
putaminal 18F-dopa uptake between 8 iPD patients and 8 atypical Parkinsonism
patients in another study, but uptake in the caudate in both groups was decreased
compared with normal controls with relatively sparing of caudate in iPD (Otsuka et al 
1 81991). F-dopa striatal uptake was correlated with the duration and severity assessed 
by H&Y in MSA patients (Brooks et al 1990). Antonini et al (1997) confirm that 18F- 
dopa PET was able (using discriminant function analysis, caudate and putamen 
uptake, and putamen:caudate ratio) to differentiate MSA patients from healthy 
controls but not from iPD. Also, they found significant correlation between putaminal 
18F-dopa uptake and motor score using a five-point scale for rigidity, bradykinesia and 
tremor, but no correlation was found using the H&Y scale. On the other hand, Otska 
et al (1997) showed that 18F-dopa uptake caudate-putamen index may help in 
differentiating MSA from iPD but 3 MSA patients out of 9 were mis-classified as 
iPD.
2.4.3 11 C-Raclopride PET
Many PET and SPECT tracers have been developed to study striatal dopamine 
receptor density, which is classified as: (i) Dl-like (Dl, D5) which are adenyl 
cyclase-dependent and (ii) D2-like (D2, D3, D4) which are not (Brooks 1993).
These receptors are present equally in the striatum. D l receptors are primarily present 
on the neurones forming the direct pathway, whereas D2 receptors are present on the 
neurones of the indirect pathway (Strange 1993, Brooks 1993).
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Brooks et al (1992a) reported normal or raised striatal D2 n C-raclopride binding 
potential in untreated iPD patients, and a decline in the receptor density in SND, PSP, 
and treated iPD with fluctuating response to levodopa, caudate being severely affected 
in PSP patients. This decline was less severe in PSP and SND patients than in treated 
iPD patients. An increase in striatal n C-raclopride binding in untreated iPD patients 
was reported in another series, which was higher in the striatum or putamen 
contralateral to the more affected side (Rinne et al 1993,1995).
Antonini et al (1997) reported that D2 u C-raclopride binding using PET was 
significantly reduced in both caudate and putamen in MSA when compared with 
healthy controls, and only in putamen when compared with iPD patients, showing the 
ability of n C-raclopride PET to help in differentiating MSA from healthy controls and 
iPD, but not iPD from healthy controls. Also, they reported significant correlation 
between putaminal D2 n C-raclopride binding and the H&Y scale as well as motor 
score using a five-point scale for rigidity, bradykinesia and tremor.
Other studies using the PET tracer n C-methylspiperone have shown normal striatal 
uptake in four untreated iPD patients (Leenders et al 1985). Striatal uptake was 
normal in another study of 6 treated patients, and slightly increased in two untreated 
iPD patients, while in contrast 6 SND patients showed a marked decrease in striatum 
uptake (Shinotoh et al 1993).
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2.5 SPECT STUDIES
2.5.1 123Iodobenzamide SPECT (123I-IBZM-SPECT)
A 123I-IBZM SPECT study of 83 iPD patients, 13 PSP or MSA cases, and 14 controls 
compared to apomorphine testing and long-term oral dopaminergic therapy responses 
during 4 months of follow-up was reported. 20% of iPD patients had a decreased I- 
IBZM uptake, and none of these cases had a positive apomorphine test. The majority
1 O'!of iPD patients with normal I-IBZM binding had a positive apomorphine challenge 
and positive response to long-term therapy. On the other hand, all patients with MSA 
or PSP had abnormal I-IBZM binding, and 6 of these patients failed to respond to 
apomorphine challenge or long-term dopaminergic therapy; the other 7 did not have 
apomorphine challenge but they did not respond to long-term dopaminergic therapy.
It has been postulated that patients with a normal 123I-IBZM binding and positive
I ' j ' i
apomorphine tests are likely to have iPD while patients with reduced I-IBZM 
binding and a negative apomorphine test are unlikely to have iPD. The importance of 
these observations is the fact that de novo patients have inadequate clinical features to 
allow accurate differential diagnosis, but SPECT and challenge testing allow for
1 73greater accuracy of diagnosis at the early stage. Patients with normal I-IBZM 
binding and a negative apomorphine testing are left as having an uncertain diagnosis 
(Schwarz et al 1993). A highly significant loss of striatal uptake of I23I-IBZM in 17 
MSA and 4 PSP patients was confirmed in another study, and a reduced basal ganglia 
to frontal lobe ratio was shown in 5 PSP patients but not in another three (van Royen 
et al 1993, Arnold et al 1994). In another study of 55 patients with parkinsonism in 
whom the response to dopaminomimetic therapy was not clear, 123I-IBZM SPECT 
accurately predicted the response to apomorphine challenge in 84% of patients. Eight
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of the nine patients who developed clinical features indicating a diagnosis other than 
iPD had reduced uptake (Schwarz et al 1997). Schwarz et al (1998a) found significant 
correlation of the results of 123I-IBZM SPECT with the long-term response to 
dopaminomimetic therapy, the development of motor fluctuations and clinical signs 
incompatible with iPD.
In a comparative study of 123I-IBZM with n C-raclopride PET in 19 iPD patients and 2 
patients with atypical parkinsonism the qualitative D2 dopamine receptor binding 
results were equal (Schwarz et al 1994).
191It can be concluded that most patients with MSA and PSP have reduced I-IBZM
191  191uptake while in iPD striatal I-IBZM uptake is usually normal. Combining I- 
IBZM with apomorphine testing predicts long-term dopaminergic therapy 
responsiveness. However, a few iPD with normal 123I-IBZM uptake have a poor 
response to treatment, and a small group of PS patients have normal 123I-IBZM, 
making the interpretation of normal striatal D2 binding difficult in some parkinsonian 
patients.
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iCHAPTER 3 
THE DOPAMINE TRANSPORTER SYSTEM
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3.1 INTRODUCTION
The dopamine transporter, or re-uptake site, is a Nao/Cb dependent pre-synaptic 
protein located on the membrane of dopaminergic neurone terminals, which projects 
from the substantia nigra to the striatum. Its function is to actively re-uptake dopamine 
from the synaptic cleft after the termination of its interaction with the dopamine 
receptors on the post-synaptic neurone, therefore controlling dopamine levels 
(Rudnick and Clark 1993, Amara et al 1993, Jaber et al 1997) (Figure 3.1).
Pathologically iPD is characterised by severe degeneration of dopaminergic neurones 
in the substantia nigra, while results in a marked decrease in striatal dopamine and a 
parallel loss of the dopamine transporter, as shown in postmortem studies (Kaufman 
and Madras 1991, Niznik et al 1991). This makes the dopamine transporter a potential 
surrogate marker for dopaminergic nigrostriatal neurones.
Using PET or SPECT to image dopamine transporters assesses the integrity of the 
nigrostriatal dopaminergic system, and different ligands have been developed for this 
purpose.
3.1.1 PET
n C-nomifensine has been used in PET studies, and shows a significantly reduced 
uptake in striatum especially putamen in iPD compared with healthy controls. 
Putamen uptake side-to-side differences was also correlated with left-right differences 
of motor function (Tedroff et al 1988, Leenders et al 1990).
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The labelled cocaine-like ligand n C-WIN35,428 also shows marked loss of dopamine 
transporters in caudate and putamen, especially its posterior portion (Frost et al 1993). 
Using a similar ligand, [UC] RTI-32, a PET study in 11 early iPD patients with an 
average UPDRS motor score of 11 compared to 10 healthy control, a significant 
reduction in the uptake was found in the putamen, again more in the posterior portion, 
but not in the caudate. No correlation between uptake and UPDRS was found 
(Guttman et al 1997).
3.1.2 SPECT
19^Bilateral loss in striatal I-P-CIT uptake using SPECT was shown in 
hemiparkinsonism (Marek et al 1996, Brucke et al 1997). In a study of 113 iPD, 9 
MSA, and 4 PSP patients 123I-p-CIT SPECT demonstrated bilateral asymmetrical loss 
of dopamine transporters. It was not possible however, to differentiate between iPD, 
MSA, and PSP. There was correlation between 123I-P-CIT binding ratios and severity 
of the parkinsonism assessed by H&Y and UPDRS. This correlation was significant 
for total UPDRS motor score, activities of daily living, rigidity, akinesia, and axial 
symptoms but not tremor (Brucke et al 1997). In another study, H&Y scale, total 
UPDRS, motor UPDRS, and UPDRS bradykinesia but not the tremor measures were
19^correlated with age-corrected specific to non-displaceable striatal I-p-CIT uptake. 
Interestingly, ipsilateral but not contralateral putamenxaudate ratio correlated with 
the total UPDRS but not other measures (Seibyl et al 1995). Recently, 123I-p-CIT 
uptake was shown to be reduced in putamen in both iPD and PSP patients. However, 
PSP patients demonstrate a significantly reduced uptake of 72% in the head of the 
caudate compared to only a 47% reduction in iPD, enabling 10 out of 13 iPD cases to
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be differentiated from PSP. No correlation between disease duration or severity using 
H&Y and UPDRS scale was found (Messa et al 1998).
123I-P-CIT SPECT imaging is reproducible with a correlation coefficient of 96% for 
the ratio of specific striatal uptake to non-specific uptake, and 98% for the total 
specific striatal uptake expressed as a percentage of injected radioactivity in 7 iPD 
patients and 7 healthy controls (Seibyl et al 1997).
199A practical disadvantage of I-p -CIT is its slow kinetics, as striatum radioactivity 
increases for 20 hours after injection, so that imaging is undertaken on the day after 
injection (Laruelle et al 1994). On the other hand 123I-FP-CIT, which shows marked 
association with dopamine transporters in animal studies (Booij et al 1997a), and has 
tested in iPD and healthy volunteers shows faster kinetics allowing SPECT imaging to 
be taken 3-6 hours after injections (Booij et al 1998a, 1999).
A comparison of 123I FP-CIT with 123I-P-CIT was undertaken in 5 drug-naive iPD 
patients who had two consecutive SPECT scans 12 weeks apart using both ligands. 
The uptake ratio of both ligands, in caudate and putamen, when expressed as a 
percentage of healthy controls showed similar decreases and variability of data. 
Therefore, 123I-FP-CIT and 123I-p -CIT offer equal quality in assessment of 
dopaminergic deficit in iPD (Booij et al 1997b).
1 99I-FP-CIT striatal uptake is reduced using SPECT in early and advanced iPD and 
also in hemiparkinsonism. No correlation between uptake and disease motor severity 
assessed by the UPDRS motor section was found (Booij et al 1997c, Tissingh et al
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1998), which contrasts with results from a 123I-p -CIT study (Brucke et al 1997). On 
the other hand Ishikawa et al (1996) showed a correlation between iPD severity and 
123I-FP-CIT in 12 mildly affected patients (H&Y I and II).
123I-FP-CIT SPECT is reliable and reproducible, based on a study of 10 iPD patients 
and 6 healthy volunteers, with a correlation coefficient of 100% using a region of 
interest protocol to measure the ratio of the striatal to non-specific uptake, and a 
correlation of 96% using volume of interest protocol (Booij et al 1998b).
In conclusion 123I-FP-CIT SPECT is a reliable method to assess dopamine 
transporters and therefore the pre-synaptic dopaminergic nerve terminals. With it is 
fast kinetics 123I-FP-CIT has a major advantage over 123I-P-CIT in routine clinical 
practice.
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Figure 3.1 A  schematic diagram of the dopaminergic nerve terminal.
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CHAPTER 4 
STUDY 1
123I-FP-CIT SPECT IMA GING AS A TOOL TO 
DIFFERENTIA TE PARKINSONISM AND 
ESSENTIAL TREMOR
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4.1 INTRODUCTION
Essential tremor is one of the conditions most commonly misdiagnosed as 
parkinsonism, and early clinical differentiation between these conditions can be 
difficult, with up to 29% of patients initially diagnosed as iPD later having their 
diagnosis changed to ET (Marshall 1962, Critchley 1972, Marttila et al 1976a, Larsen 
and Caine 1983, Koller 1984, Meara et al 1999). Differentiation between 
parkinsonism and ET is important in defining prognosis, which is relatively benign in 
ET compared with parkinsonism, in treatment decisions, and in defining patients 
accurately for research. There is therefore a need to improve the accuracy of 
differentiating patients with ET from those with parkinsonism. Also, differentiation of 
iPD from other causes of parkinsonism, mainly MSA and PSP can be difficult and 
clinico-pathological studies suggest that the clinical diagnosis of iPD is only 76% 
reliable (Hughes et al 1991, Rajput et al 1991a).
The aim of this study is to assess the clinical application of 123I-FP-CIT SPECT to 
differentiate between parkinsonism and ET and to assess whether this technique can 
help in differentiating between iPD, MSA, and PSP.
4.2 METHODS
4.2.1 Study subjects
Parkinsonian syndrome and essential tremor patients were selected from patients 
attending the movement disorder clinics or general neurology clinics. Healthy 
volunteers were selected from patient spouses and via advertisement at the study site.
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Patients of either sex, within an age of 40-80 years, were first defined as having 
Parkinsonian syndrome (PS) and secondly classified as iPD, MSA, PSP, each on the 
basis of standard clinical criteria. Thus patients were selected on the basis of 
bradykinesia with rigidity and/or tremor, as defined by UK Brain Bank criteria step 1 
(Gibb and Lees 1988), without evidence of cerebrovascular disease, structural brain 
disease (cranial imaging if clinically suspected), dementia, head injury or encephalitis. 
Thereafter disease specific criteria were applied, as follows:
For idiopathic Parkinson Js Disease: Patients with established disease were required 
to fulfil the UK Brain Bank criteria step 3 - supportive prospective positive criteria, 
thus three or more from unilateral onset, rest tremor, progressive, persisting 
asymmetry affecting side of onset most, excellent response (70-100%) to levodopa, 
severe levodopa-induced chorea, levodopa response for 5 years or more, and clinical 
course of 10 years or more. However, de novo patients were required only to have a 
positive response to apomorphine or levodopa challenge test which was defined as an 
improvement of at least 30% determined by using the UPDRS - motor section.
For Multiple System Atrophy: Consensus Committee of the American Autonomic 
Society and the American Academy of Neurology diagnostic criteria (1996) were 
applied: (i) Parkinsonism (bradykinesia with rigidity or tremor or both), usually with a 
poor or unstained motor response to chronic levodopa therapy; (ii) Cerebellar or 
corticospinal signs; (iii) Orthostatic hypotension, impotence, urinary incontinence or 
retention, usually preceding or within 2 years after the onset of the motor symptoms.
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For Progressive Supranuclear Palsy: The National Institute of Neurological 
Disorders and Stroke and the Society for PSP clinical research diagnostic criteria was 
applied (Litvan et al 1996) being a gradual, progressive disorder, onset at age 40 years 
or older, vertical supranuclear palsy, and prominent postural instability with falls in 
the first year of disease onset, as mandatory criteria, and supported by any of the 
following: slowing of vertical saccades, symmetric akinesia or rigidity proximal more 
than distal, abnormal neck posture, especially retrocollis, early dysphagia and 
dysarthria, early onset of cognitive impairment with at least two of apathy, 
impairment in abstract thought, decreased verbal fluency, utilisation or imitation 
behaviour, or frontal release signs; and with evidence of a poor or absent response to 
chronic levodopa therapy. For PSP, exclusion of clinical features suggesting 
alternative diagnoses such as Cortico-Basal Ganglionic Degeneration, Alzheimer’s 
disease, or MSA were applied.
For Essential Tremor: Patients with a working clinical diagnosis of ET were 
screened for inclusion in the study. Clinical features were reassessed according to 
Findley and Koller (1994), thus excluding patients with abnormal neurological signs, 
causes of enhanced physiological tremor including hyperthyroidism, exposure to 
tremorogenic drugs, possible psychogenic tremor, or with any evidence of sudden 
onset or stepwise deterioration. In addition, patients with a first degree relative 
diagnosed with iPD were excluded. The definite ET criteria were fulfilled being a 
duration of at least 5 years and bilateral postural tremor with or without kinetic 
tremor, involving hands or forearms, that is visible and persistent, with at times 
tremor of other body parts, bilateral postural tremor which may be asymmetric, tremor
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reported by the patient to be persistent although the amplitude may fluctuate and 
tremor not necessarily producing disability.
Healthy volunteers of either sex, within an age range of 50-80 years, underwent a 
general health screening questionnaire and clinical examination, and had no history of 
psychiatric illness.
For all patients with PS or ET and for volunteers, any drug intake with the potential to 
interact with striatal uptake of 123I-FP-CIT by the dopamine transporter was 
disallowed, such as some CNS stimulants (amphetamine), anti-anorexia and obesity 
treatments, sympathomimetics including some nasal decongestants, the anti­
depressants amoxapine and buspirone, and anti-parkinsonian drugs selegiline and 
benztropine. The minimum wash out period for all such therapy was 4 weeks except 
for selegiline which was 7 days, and was considered sufficient to eliminate its 
amphetamine by-products. Standard comorbid renal, hepatic, and cardiac conditions 
and drug or alcohol misuse were excluded.
4.2.2 Study assessments
Six European centres were involved in the study, because of the large number of 
patients required for the study (section 4.2.5), which could take a single centre 
between 4 and 12 years to recruit the subjects. The Glasgow centre was the largest 
contributor (more than 30% of the study subjects).
Patients and volunteers gave written informed consent and the study was approved by 
the Ethics Committee in each study site. Standard safety assessments (vital signs,
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physical examination, laboratory tests) were conducted at baseline and repeated at
|
i
| least twice during the study period. Parkinsonian syndrome patients were assessed 
using UPDRS motor section and H&Y rating scales in ‘practically-defined o ff, 
following withdrawal of anti-parkinsonian therapy for 12 hours.
Patients and healthy volunteers reported any adverse events occurring after 
123I_FP-CIT injection, with a follow-up visit at 24-72 hours and a seven day telephone 
questionnaire. Female subjects of reproductive age were advised to avoid conception 
for at least three complete menstrual cycles post-injection.
4.2.3 Imaging
All subjects underwent thyroid blocking according to an established site protocol. An 
intravenous injection of 123I-FP-CIT containing activity in the range 111-185 MBq 
was given over approximately 15 seconds followed by a saline flush. SPECT imaging 
was conducted 3-6 hours post-injection. SPECT images were obtained using a site 
specific gamma camera system (multi-detector single slice system in 3 centres, a 
triple headed camera system in 2 centres and a double headed camera system in one 
centre). Each system provided transverse slices with clear visualisation of the head of 
the caudate nucleus and putamen.
4.2.4 Data analysis 
Visual Assessment
The primary endpoint for the study was designated the institutional read, and 
consisted of visual assessment of 123I-FP-CIT striatal uptake. This was conducted on 
scans reconstructed to the highest usable resolution in each centre by an investigator
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blinded to clinical data. The secondary endpoint of the study was designated the 
consensus blinded read, and was conducted on uniform reconstruction of electronic 
raw data using an identical colour scale and format for each image. The resultant hard 
copy images were randomised for the blinded read panel, consisting of a neurologist 
with limited experience in assessing 123I-FP-CIT images and four nuclear medicine
19^physicians experienced in I-FP-CIT imaging. Each panel member evaluated the 
SPECT images independently and blinded to the clinical data. Where there was 
agreement from three or more individual blinded readers, this was taken as the 
consensus blinded read.
A predefined classification was used, as follows (Figure 4.1):
Normal: characterised by uptake of the tracer in both right and left putamen and 
caudate nuclei. The image is largely symmetrical with approximately equal levels of 
uptake on both left and right sides. Activity is contained close to the centre image, 
forming two crescents shaped areas of uptake.
Abnormal: can be described in one of three ways:
(i) A bnorm al123I-FP-CIT SPECT image grade 1:
Uptake is symmetrical with almost normal or reduced putamen activity in one 
hemisphere and a significantly lower or absent uptake in the putamen on the other 
side.
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(ii) Abnorm al123I-FP-CIT SPECT image grade 2:
Uptake is significantly reduced in the putamen on both the right and left sides. 
Activity is confined to the caudate nuclei and forms two roughly circular areas.
(iii) Abnorm al123I-FP-CIT SPECT image grade 3:
Uptake is virtually absent from both putamen and caudate nuclei on each side of the 
brain resulting in a significant reduction in contrast and the visualisation of 
background activity throughout the rest of the image.
Semi-quantitative assessments
All data were collected and analysed in one centre in standardised form. Semi- 
quantitative assessment was based on region of interest (ROI) analysis. The total 
amount of tracer in the striatum consists of dopamine transporter bound ligand and 
nonspecifically bound ligand. A correction for nonspecifically bound 123I-FP-CIT is 
made as follows, uptake per unit area in a reference region, representing nonspecific 
uptake, is subtracted from the total recorded activity uptake per unit area in the 
striatum. The occipital cortex was used as a suitable reference region, being nearly 
devoid of dopamine transporter binding sites but receiving an equal supply of tracer 
from the vascular compartment.
A standard template was used, with fixed ROIs corresponding to caudate nucleus, 
putamen and occipital cortex according to the stereotactic atlas of Matsui and Hirano 
(1978). For analysis of the regional activity distribution in various images, the size 
and shape of each structure shown on the template was not changed and the 
template’s region of interest was placed over the image corresponding to each of the 
regions of interest.
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Semi-quantitative ROI analysis was used as a secondary study endpoint. Three 
measurement methods were adopted:
4.2.5 Statistical analysis
Sample size was based on a one-sided 5% significance level, a power of 80%, and on 
the assumption that 95% of parkinsonism patients have abnormal 123I-FP-CIT striatal 
uptake, and 5% of ET patients have abnormal 123I-FP-CIT uptake. This was calculated 
as 118 parkinsonism patients, and 30 ET patients.
Sensitivity of 123I-FP-CIT striatal uptake for parkinsonism was calculated as number 
of abnormal SPECT images / (number of abnormal SPECT images + number of 
normal SPECT images). Specificity for ET was calculated as number of normal 
SPECT images / (number of normal SPECT images + number of abnormal SPECT 
images).
Both per-protocol (all subjects enrolled with an available 123I-FP-CIT SPECT image 
who did not violate the protocol), and intention-to-treat analysis (all subjects recruited 
with an available 123I-FP-CIT SPECT image) were conducted. Analysis of variance 
models presented type III sums of squares. Response rates used a one sided 95% 
confidence lower boundary level. All p-values were two-sided and set at 5% 
significance. Differences in binary response rate of abnormal/normal striatal uptake
Specific :nonspecific ratio 
(SP:NS)
Specific uptake in striatal ROI 
Mean occipital ROI uptake
Putamenxaudate ratio Specific uptake in putamen ROI 
Specific uptake in caudate ROI
Asymmetry Index 
(AI)
lOOx (Specific uptake ipsilateral-contralaterall 
0.5x(Specific uptake ipsilateral+contralateral)
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were analysed using Fisher’s exact and Wilcoxon rank sum tests as appropriate. For 
semi-quantitative analysis, ANOVA techniques were used.
Comparisons of striatal uptake in iPD, MSA, PSP and healthy volunteers were made 
by one-way analysis of variance with Bonferroni correction for pre-specified multiple 
comparisons.
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Figure 4.1 Example of 123I-FP-CIT images in normal and parkinsonism cases.
A) Normal tracer uptake in both right and left putamen and caudate nuclei.
B) Abnormal image grade 1: Asymmetric uptake with normal or almost normal 
putamen activity in one hemisphere and with a more marked reduction in the 
contralateral putamen (arrow).
C) Abnormal image grade 2: Significant bilateral reduction in putamen uptake, with 
activity confined in the caudate nuclei (arrows).
D) Abnormal image grade 3: Virtually absent uptake bilaterally affecting both 
putamen and caudate nuclei.
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4.3 RESULTS
4.3.1 Study Pop ulations
Two hundred and ten patients and 38 matched healthy volunteers (Tables 4.1,4.2) 
were screened, 177 (84.3%) diagnosed clinically as parkinsonism and 33 (15.7%) as 
ET. The parkinsonism patients were further classified as iPD 145 (82%), MSA 22 
(12%) and PSP 10 (6%). Of the twenty one patients and 3 healthy volunteers excluded 
from the study, most withdrew consent, and in addition 4 patients did not have 
SPECT images after receiving I FP-CIT injections (three due to failure of the 
imaging equipment and one withdrew from the study after receiving the injection). Of 
the 220 subjects who had SPECT images and were defined as intention-to-treat, 63 
were excluded from per-protocol analysis, mainly because of injection dosage being 
outwith the range 111-185 MBq and/or had imaging was performed outside the 3-6 
hour post-injection interval (n=51). Fourteen cases were excluded from per-protocol 
analysis because of errors in recording clinical criteria therefore they failed one or 
more inclusion/exclusion criteria.
In Glasgow, cases were identified for possible inclusion by reviewing the hospital 
case records of 211 patients mostly attending the movement disorder clinic, and 41 
patients with a diagnosis other than iPD, MSA, PSP or ET and a further 57 patients 
were excluded as unsuitable mainly because of concomitant disease, or distance from 
hospital. Of the remainder 113 patients, 24 patients were not able to attend and 89 
patients and 7 healthy volunteers were asked to participate, and 12 patients declined. 
Seventy-seven patients (51 iPD, 9 MSA, 3 PSP, and 14 ET) and seven healthy 
volunteers were screened; nine patients and one healthy volunteer withdrew consent. 
A further 7 patients were excluded from the study, of whom three failed inclusion
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criteria, one had abnormal laboratory results, and three had unobtainable SPECT 
images for technical reasons. A total of 6 healthy volunteers, 44 iPD, 6 MSA, 3 PSP, 
and 8 ET contributed to the study at the Glasgow site. Of the 67 subjects who have 
SPECT images, 3 were included in intention-to-treat analysis but excluded from per- 
protocol analysis because of errors in recording clinical criteria.
The H&Y score in intention-to-treat patients was I in 35 cases, II in 48 cases, III in 25 
cases, IV in 17 cases and V in 5 cases, and in per-protocol patients was I in 23 cases, 
II in 38 cases, III in 14 cases, IV in 14 cases and V in 4 cases. The median UPDRS 
motor score was 21 (interquartile range 14-34).
4.3.2 Visual Assessments
Institutional read
In the per-protocol population the institutional reading scored 111 of 115 (96.5%) 
cases of parkinsonism abnormal, all 16 cases (100%) of ET as normal, and all 26 
healthy volunteers as normal (100%). For the intention-to-treat population 154 of 158 
(97.5%) cases of parkinsonism score abnormal, all 27 cases (100%) of ET score 
normal, and 34 of 35 healthy volunteers scored normal (97.1%) (Table 4.3). The 
institutional read was not able to differentiate between iPD, MSA and PSP (Table 
4.4).
The overall sensitivity for the per-protocol and intention-to-treat populations for the 
institutional read was 97% and specificity was 100%.
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In the institutional read the 4 parkinsonism patients with a normal 123I-FP- CIT study 
were common to the per-protocol and intention-to-treat groups. Three had a clinical 
diagnosis of iPD and one had PSP.
Consensus blinded read
In the per-protocol population the blinded reading scored 109 of 115 (94.8%) cases of 
parkinsonism abnormal, 15 of 16 cases (93.8%) with ET as normal, and 24 of 26 
(92.3%) healthy volunteers as normal. For the intention-to-treat population 150 of 158 
(94.9%) cases of parkinsonism scored abnormal, 25 of 27 (92.6%) ET scored normal, 
and 33 of 35 (97.1%) healthy volunteers scored normal (Table 4.3). The blinded read 
was not able to differentiate between iPD, MSA and PSP.
The overall sensitivity for the per-protocol and intention-to-treat populations for the 
blinded read was 94.8% and specificity was 93.2%.
Of the 150 patients with parkinsonism who scored abnormal in the consensus blinded 
read, there was agreement amongst all 5 investigators in 143 patients; 6 patients were 
scored abnormal by 4 of 5 investigators; and 1 patients was scored abnormal by 3 of 5 
investigators. Four patients with parkinsonism were scored normal by all 5 
investigators; 3 parkinsonism patients were normal according to 4 of 5 investigators; 1 
additional case was scored normal by 3 of 5 investigators. In the healthy volunteers 29 
of 33 were scored normal by all 5 investigators, 3 were scored normal by 4 of 5 
investigators and one patient was scored normal by 3 of 5 investigators. One of two 
controls was scored abnormal by 4 of 5 investigators while one was scored abnormal 
by 3 of 5 investigators.
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In addition to the 4 parkinsonian patients scored as normal in the institutional read, 4
i
j more parkinsonian patients were scored as normal by the blinded read of whom 2 had 
a clinical diagnosis of iPD, and 2 had a clinical diagnosis of MSA. Two patients with 
clinical diagnosis of ET were scored abnormal in the blinded read.
Visual assessment in mild unilateral iPD (H&YI)
Of the 23 iPD cases with H&Y stage I (in the per-protocol analysis group), only one 
patient scored normal by the institutional read. Of the 35 iPD cases with H&Y stage I 
(in the intention-to-treat analysis group), only one scored normal in the institutional 
read. The same result was obtained in the blinded read for the 23 iPD cases in the per- 
protocol analysis group i.e. one patient was scored normal. Of the 35 iPD cases (H&Y 
I, intention-to-treat analysis group), the blinded read scored normal in 2 cases.
Correlation o f visual assessment with disease severity and duration 
The grading of the institutional read of 41 iPD patients (Glasgow site) was 
significantly correlated with the disease severity assessed by H&Y (r=-0.59, 
p<0.000T) and UPDRS (r=-0.52, p=0.0006). Also, there was significant correlation 
between disease duration and visual grading (r=-0.62, p<0.0001).
Effect o f the disease severity on the visual assessment
There was no effect of H&Y grade for abnormal/normal striatal uptake in either 
institutional read for per-protocol iPD cases (p=0.689) or intention-to-treat iPD 
patients (p=0.716) or in the consensus blinded read for per-protocol iPD (p=0.662) or 
intention-to-treat iPD patients (p=0.337) (Table 4.5).
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Effect o f  investigational centre on the visual assessment
There was no effect of investigation centre for abnormal/normal striatal uptake in 
either institutional read for per-protocol PS (p=0.327) or ET or intention-to-treat PS 
(p=0.456) or consensus blinded read for per-protocol PS (p=0.06) or ET (p=0.125) 
and intention-to-treat PS (p=0.227) or ET (p=0.182). The data for institutional read 
and blinded read according to investigation centre is shown in Table 4.6, the tabular 
score is provided on the basis that PS patients are expected to have an abnormal scan 
and that ET patients are expected to have a normal scan.
Effect o f age on the visual assessment
There was no effect of age for abnormal/normal striatal uptake in either institutional 
read for per-protocol PS (p=0.942) or ET and intention-to-treat PS (p=0.838) or 
consensus blinded read for per-protocol PS (p=0.774) or ET (p=0.723) or intention-to- 
treat PS (p=0.93) or ET (p=0.884) (Table 4.7).
4.3.3 Semi-quantitative Analysis
Specific:nonspecific uptake ratios
There were no differences in mean striatum, caudate, or putamen SP:NS ratios 
between ET patients and healthy volunteers. Uptake ratios were however significantly 
reduced in parkinsonism (p<0.001) (Figure 4.2). Also, patients with unilateral iPD 
(H&Y I) showed significant reduction in SP:NS putamen uptake bilaterally (Figure 
4.3). There were no significant differences in the mean striatum, caudate, or putamen 
uptake ratios between iPD, MSA, and PSP (Figure 4.4).
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Asymmetry index
There were no differences in mean striatum, caudate, or putamen asymmetry indices 
between ET patients and healthy volunteers, however the indices were significantly 
high in parkinsonism (p<0.001) (Figure 4.5).
There were no significant differences in the striatum or caudate asymmetry indices 
between iPD [7.1 (C l5.5, 8.7), 8.2 (6.3, 10)], MSA [2.4 (-2.5, 7.3), 3.6 (-3, 10)] and 
PSP [-0.68 (-7.4,6.0), -0.76 (-7.4, 5.9)] but putamen asymmetry index was 
significantly lower in MSA (p<0.01) and PSP (p<0.001). There was overlap between 
the asymmetry indices in the three groups but patients with an asymmetry index 
greater than 5.0 were more likely to have iPD than either MSA or PSP (Figure 4.6).
Putamen:caudate ratios
There were no differences between putamenrcaudate ratios between ET patients and 
healthy volunteers, however the ratios were significantly reduced in parkinsonism 
(p<0.001) (Figure 4.7). Moreover, there were no significant difference in the 
putamen:caudate ratios between iPD, MSA, and PSP (Figure 4.8).
4.3.4 Adverse Events
Of these adverse events 2 were considered severe. One patient had headache and the 
one had extrapyramidal symptoms, but neither was considered by the investigator to 
be related to 123I-FP-CIT injection. Of 65 adverse events in 36 subjects, (43 in 
parkinsonism cases, 13 in ET cases, and 9 in healthy volunteers), thirty (46%) were
1 9Tthought to be probably or possibly related to I-FP-CIT, adverse events reported in 
more than 1% of the 224 subjects is shown in Table 4.8.
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Table 4.1 Study population: 158 patients with parkinsonian syndrome, 27 with 
essential tremor and 35 healthy volunteers
248 Subjects Screened
220 subjects included and 28 subjects excluded
Per-protocol Intention-to-treat
Parkinsonian Syndrome 115 158
Idiopathic Parkinson’s disease 93 130
Multiple system atrophy 14 18
Progressive supranuclear palsy 8 10
Essential Tremor 16 27
Healthy volunteers 26 35
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Table 4.2 Demographic data of 158 patients and 35 healthy volunteers enrolled to 123I- 
FP-CIT SPECT.
Parkinsonism Essential Tremor Healthy Volunteers
Intent- per- Intent- per- Intent- per-
to-treat protocol to-treat protocol to-treat protocol
(n=158) (n=115) (n=27) (n=16) (n=35) (n=26)
Institutional Normal 4 4 27 16 34 26
read (2.5%) (3.5%) (100%) (100%) (97.1%) (100%)
Abnormal 154 111 0 0 1 0
(97.5%) (96.5%) (0%) (0%) (2.9%) (0%)
Consensus Normal 8 6 25 15 33 24
blinded read (5.1%) (5.2%) (92.6%) (93.8%) (94.3%) (92.3%)
Abnormal 150 109 2 1 2 2
(94.9%) (94.8%) (7.4%) (6.3%) (5.7%) (7.7%)
Data are mean (SD)
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1 9 1Table 4.3 Results of institutional read and consensus blinded read of I-FP-CIT
SPECT according to clinical diagnosis.
Parkinsonism Essential Tremor Healthy
Volunteers
Intent-to-
treat
(n=158)
per-
protocol
(n=115)
Intent-
to-treat
(n=27)
per-
protocol
(n=16)
Intent- per- 
to-treat protocol 
(n=35) (n=26)
Institutional
read
Normal 4
(2.5%)
4
(3.5%)
27
(100%)
16
(100%)
34
(97.1%)
26
(100%)
Abnormal 154
(97.5%)
111
(96.5%)
0
(0%)
0
(0%)
1
(2.9%)
0
(0%)
Consensus 
blinded read
Normal 8
(5.1%)
6
(5.2%)
25
(92.6%)
15
(93.8%)
33
(94.3%)
24
(92.3%)
Abnormal 150
(94.9%)
109
(94.8%)
2
(7.4%)
1
(6.3%)
2
(5.7%)
2
(7.7%)
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Table 4.4 I-FP-CIT institutional read results according to type of parkinsonism in
the intention-to-treat population.
Normal Abnormal
Grade 1 Grade 2 Grade 3
Idiopathic Parkinson’s disease 
(n=130)
3 30 68 29
Multiple system atrophy 
(n=18)
0 2 10 6
Progressive supranuclear palsy 
(n=10)
1 1 4 4
Normal (grade 0): Symmetrical uptake in both right and left caudate and putamen. 
Abnormal (grade 1): Uptake is symmetrical with almost normal or reduced putamen 
activity in one hemisphere and a more marked change on the other side.
Abnormal (grade 2): Uptake is significantly reduced in the putamen on both the right 
and left sides.
Abnormal (grade 3): Uptake is virtually absent from both putamen and caudate nuclei 
on each side.
For more detailed definition o f abnormal scan types, see methods section.
63
Table 4.5 123I-FP-CIT institutional read results according to severity of idiopathic
Parkinson’s disease as assessed by H&Y scale.
Institutional read 
per-protocol ITT
Blinded read 
per-protocol
I
ITT
H&Y I 95.7% (22/23) 95.1% (34/35) 95.7% (22/23) 94.3% (33/35)
H&Y II 97.4% (37/38) 97.9% (47/48) 94.4% (36/38) 95.8% (46/48)
H&Y III 92.9% (13/14) 96.0% (24/25) 92.9% (13/14) 96.0% (24/25)
H&Y IV 100% (18/18) 100% (22/22) 100% (18/18) 100% (22/22)
ITT = intention-to-treat 
H&Y = Hoehn and Yahr
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Table 4.6 123I-FP-CIT institutional read results according to study centre in patients
with parkinsonian syndrome and essential tremor.
Institutional read Blinded read
Population per-protocol ITT per-protocol ITT
Parkinsonian
syndrome
Centre I 100% (9/9) 100% (23/23) 100% (9/9) 95.7% (22/23)
Centre II 94.7% (18/19) 96% (24/25) 94.7% (18/19) 96% (24/25)
Centre III 98% (49/50) 98.1% (52/53) 98% (49/50) 98.1% (52/53)
Centre IV 95.8% (23/24) 96.2% (25/26) 91.7% (22/24) 92.3% (24/26)
Centre V 100% (8/8) 100% (21/21) 100% (8/8) 95.2% (20/21)
Centre VI 80% (4/5) 90% (9/10) 60% (3/5) 80% (8/10)
Essential
tremor
Centre I 100% (1/1) 100% (5/5) 0.0% (0/1) 60% (3/5)
Centre II 100% (2/2) 100% (5/5) 100% (2/2) 100% (5/5)
Centre III 100% (8/8) 100% (8/8) 100% (8/8) 100% (8/8)
Centre IV 100% (2/2) 100% (2/2) 100% (2/2) 100% (2/2)
Centre V 100% (2/2) 100% (4/4) 100% (2/2) 100% (4/4)
Centre VI 100% (1/1) 100% (3/3) 100% (1/1) 100% (3/3)
ITT = intention-to-treat
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Table 4.7 123I-FP-CIT institutional read results according to age in patients with
parkinsonian syndrome and essential tremor.
Age
Institutional read 
per-protocol ITT
Blinded read 
per-protocol ITT
Parkinsonian 31-40 100% (1/1) 100% (1/1) 100% (1/1) 100% (1/1)
syndrome 41-50 90% (9/10) 94.1% (16/17) 90% (9/10) 94% (16/17)
51-60 100% (27/27) 100% (40/40) 96.3% (26/27) 95% (38/40)
61-70 96.1% (49/51) 97% (65/67) 94.1% (48/51) 95.5% (64/67)
71-80 96.2% (25/26) 97% (32/32) 96.2% (25/26) 93.9% (31/33)
Essential 40-50 100% (1/1) 100% (2/2) 100% (1/1) 100% (2/2)
tremor 51-60 100% (5/5) 100% (7/7) 100% (5/5) 100% (7/7)
61-70 100% (8/8) 100% (11/11) 87.5% (7/8) 81.1% (9/11)
71-80 100% (2/2) 100% (7/7) 100% (2/2) 100% (7/7)
ITT  = intention-to-treat
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Table 4.8 Adverse events reported in more than 1% of 224 subjects given 123I-FP- 
CIT.
Adverse event Number of events in 
patients
Number of events in healthy 
volunteers
Headache 15 2
Flu like symptoms 4 2
Injection site bleeding 4 1
Vertigo 4 0
Paras thesia 3 0
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Figure 4.2 Mean specific:nonspecific uptake ratio in per-protocol patients with 
parkinsonism (n=l 15), essential tremor (n=16) and healthy volunteers (n=27).
Specific :nonspecific ratio is significantly reduced in parkinsonism as compared to 
essential tremor and healthy volunteers (p<0.001).
Data are mean and 95% confidence interval.
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Figure 4.3 Presymptomatic putamen, and early symptomatic putamen uptake ratios in 
per-protocol patients with idiopathic Parkinson’s disease (H&Y stage I, n=23) 
compared to healthy volunteers (n=26).
There was a significant reduction in both symptomatic and presymptomatic 
hemispheres (p<0.001).
Data are mean (95% confidence interval).
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Figure 4.4 Mean specific:nonspecific uptake ratio in per-protocol patients with 
idiopathic Parkinson’s disease (n=93), multiple system atrophy (n=14), and 
progressive supranuclear palsy (n=8).
No significant difference in the specific:nonspecific ratio was shown between 
idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear 
palsy.
Data are mean and 95% confidence interval.
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Figure 4.5 Asymmetry index in per-protocol patients with parkinsonism (n=l 15), 
essential tremor (n=16) and healthy volunteers (n=27).
Asymmetry index was significantly high in parkinsonism compared to essential 
tremor and healthy volunteers (p<0.001).
Data are mean and 95% confidence interval.
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Figure 4.6 Putamen asymmetry index in per-protocol patients with idiopathic 
Parkinson’s disease (n=93), multiple system atrophy (n=14), and progressive 
supranuclear palsy (n=8).
Putamen asymmetry index was significantly lower in multiple system atrophy 
(p<0.01) and progressive supranuclear palsy (p<0.001) compared to idiopathic 
Parkinson’s disease. No significant difference was found in striatum or caudate 
asymmetry index.
Data are mean and 95% confidence interval.
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Figure 4.7 Putamen:caudate ratio in per-protocol patients with parkinsonism (n=l 15), 
essential tremor (n=16) and healthy volunteers (n=27).
Putamen:caudate ratio was significantly reduced in parkinsonism compared to 
essential tremor and healthy volunteers (pcO.OOl).
Data are mean and 95% confidence interval.
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Figure 4.8 Putamen:caudate ratio in per-protocol patients with idiopathic Parkinson’s 
disease (n=93), multiple system atrophy (n=14), and progressive supranuclear palsy 
(n=8).
No significant difference was found in putamen:caudate ratio in parkinsonism 
compared to multiple system atrophy and progressive supranuclear palsy.
Data are mean and 95% confidence interval.
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! 4.4 DISCUSSION
I
| A principle aim of the present study was to examine the accuracy of using a simple
|
| visual assessment of striatal uptake rather than ratio calculations to differentiate
between parkinsonism and ET. This is important because visual assessment is clearly 
applicable in a clinical diagnostic setting.
Previous functional imaging studies have used only quantitative and semi-quantitative 
analysis in assessing striatal uptake. For example, Asenbaum et al (1998) reported a 
low specificinonspecific uptake ratio of 123I-B-CIT in 29 patients with iPD (H&Y I) 
compared to 32 patients with ET and 30 healthy volunteers. In the present study, there 
was an overall sensitivity and specificity of 96% in the two populations studied (per- 
protocol and intention-to-treat), so that striatal visual assessment represents a 
significant advance in the application of functional imaging in the diagnosis of 
parkinsonism and tremor disorders. Moreover, with no overall effect of age, disease 
severity or imaging equipment, these results should be applicable in patients at 
differing clinical stages and in different imaging centres.
Of the 35 iPD with mild unilateral disease (H&Y stage I) only one patient scored 
normal. Thus visual assessment can identify abnormalities in imaging patients in the 
early stages of their illness. The grading of the abnormal scans showed correlation 
with the H&Y staging, UPDRS and disease duration indicating that visual assessment 
may help in assessing disease onset and severity.
The cases where I-FP-CIT results were discordant with the clinical diagnosis are to 
be expected considering that the known error rate in clinical diagnosis is 18%-24%
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for iPD (Hughes et al 1992) and 10-25% for ET (Marshall et al 1962, Critchley 1972,
t
Larsen et al 1983, Brooks et al 1992b). Given the primary assumption of the study
n i
that parkinsonism cases should have abnormal I-FP-CIT uptake while ET should 
have normal uptake, these cases are of major interest. However, it is not possible 
within the constraints of this study to resolve these mismatches since no diagnostic 
gold standard, i.e. postmortem, is available. Nevertheless potential causes for the 
mismatch have been sought. One patient with normal I-FP-CIT uptake had a 5 year 
history of tremor-predominant asymmetrical parkinsonism apparently responsive to 
levodopa. However, further clinical review suggested that ET was a plausible 
alternative clinical diagnosis. Another patient was found to be have been on 
undeclared treatment with a neuroleptic drug, which may explain the clinical features 
in the presence of a normal 123I-FP-CIT uptake. However Schwarz et al (1998b) have 
described recently two patients under neuroleptic treatment in whom IPT SPECT 
showed evidence of reduced dopamine transporters. One patient had left sided 
parkinsonism for 3 years before she was diagnosed as schizophrenic and treated with 
neuroleptic drugs. The second patient suffered from paranoid psychosis for 30 years 
before he developed parkinsonism and was treated with atypical neuroleptic drug 
clozapine which is less likely to cause parkinsonian symptoms. The authors concluded 
that these two patients have a nigrostriatal defect, which could be due to iPD rather 
than drug-induced parkinsonism. Further functional neuroimaging studies are needed 
to clarify the nature of neuroleptic induced parkinsonism.
On subsequent review of two further patients with iPD and normal SPECT scans, one 
had no definite diagnosis but the possibility of cerebrovascular disease was raised and
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one was considered to have ET. There were no available follow-up data in the 
remaining patients.
Of 2 ET patients considered to have an abnormal I-FP-CIT uptake by visual 
assessment, one of them was on amitryptiline (a prohibited medication as it may 
interfere with I-FP-CIT uptake), and no follow-up data was available on the other.
The possibility of using I-FP-CIT as a diagnostic tool for atypical tremor cases is 
raised by prior PET studies. Brooks et al (1992b) found that some patients with rest 
tremor without bradykinesia, therefore not fulfilling UK brain bank criteria for iPD 
have disruption of the nigrostriatal dopaminergic system while other patients with 
predominant postural tremor, who fail Findley and Koller criteria for definite ET have 
a normal nigrostriatal system. Thus functional imaging capable of visualising the 
dopaminergic system may help in diagnosing patients presenting with tremor but not 
fulfilling established clinical criteria. In the present study all patients fulfilled standard 
clinical criteria and atypical cases which are clinically more challenging were not 
included. Even within the present study, however, there are examples of cases 
fulfilling criteria but showing discordant imaging results, which is consistent with an 
established false positive rate of diagnosis according to clinical criteria in both 
parkinsonism and ET (Brooks et al 1992b, Hughes et al 1992, Ward et al 1990). (See 
study 3, chapter 6, for patients with tremor not fulfilling diagnostic criteria).
There is conflicting evidence from the literature about the relationship between ET 
and iPD, which adds to diagnostic difficulty in atypical clinical cases, especially in 
the presence of a family history of tremor disorder. James Parkinson (1817) attempted
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to distinguish the two disorders, however Gowers drew attention to the possibility of 
an association between the two disorders as follows: “it is doubtful whether this senile 
tremor is far removed from paralysis agitans, although, as a rule, the other symptoms 
of shaking palsy remain absent. Some cases are met with a character intermediate 
between the two affections, and both may occur in different members of the same 
family”. Critchley (1949) however considered the association of these two disorders a 
chance occurrence of two relatively common disorders.
The association between ET and iPD varies amongst studies. Marttila et al (1984) 
studied ET in a Finnish population aged over 40 and concluded that iPD and ET are 
genetcally independent. This was supported by Cleeves et al (1988) in a study of 137 
ET patients, 100 iPD, and 100 controls, in which a higher family history of ET in iPD 
patierts than in control subjects was not statistically significant. None of the 169 
patierts with typical ET reported by Martinelli et al (1987) developed iPD after a 
follov/ up period of between 2 and 5 years. A retrospective study of 266 patients with 
ET showed only 2% had an additional diagnosis of iPD (Rajput et al 1984b) and 6% 
in a sxidy of 678 ET patients (Koller et al 1994). No case of iPD was found amongst 
20 E l kindreds (Bain et al 1994). On the other hand, Geraghty et al (1985) found that 
iPD oxurred 24 times more often than expected in patients with ET older than age 60, 
19 tines if all ages were included and 18 times if only patients with a duration of ET 
for fbe years or more before the onset of iPD were included. About 20% of ET 
patierts had parkinsonian features according to Lou and Jankovic (1991) but Lang et 
al (1992) criticised this study as not representing the typical clinical correlates with 
ET. Jmkovic et al (1995) found a high frequency of familial tremor among relatives 
of iPD patient compared with relatives of PSP patients and normal controls. In our
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study all ET patients scored normal in the institutional read and only two scored 
abnormal in the consensus read. These results are in agreement with published 
postmortem (Rajput et al 1991a), 18F-dopa PET (Brooks et al 1992b) and 123I-B-CIT 
SPECT (Asenbaum et al 1998) studies indicates a normal nigrostriatal pathway in ET, 
therefore supporting the evidence that ET and iPD are not associated.
Semi-quantitive analysis confirmed clearly the results from visual assessment; that
1 O'KI-FP-CIT can differentiate between parkinsonism and ET and healthy volunteers.
Also, semi-quantitive analysis using this ligand has the ability to recognise early loss 
of dopamine transporters where the symptoms are unilateral, which in is agreement 
with previous 18F-dopa PET studies (Garnett et all984, Morrish et al 1995) and 
previous SPECT studies of dopamine transporters using 123I-P-CIT and 123I-FP-CIT 
(Marek et al 1996, Booij et al 1997c, Tissingh et al 1998, Asenbaum et al 1998). The 
finding of consistently reduced uptake in the ipsilateral putamen of patients with 
unilateral disease (H&Y I) therefore reinforces the idea of a presymptomatic phase of 
iPD.
The ratio of uptake between putamen and caudate has been the subject of previous 
studies, based on the observation of earlier impaired uptake in putamen compared to 
caudate in iPD and the possibility of a different pattern of loss for other parkinsonian 
conditions such as PSP and MSA (Brooks et al 1990). Although postmortem 
investigations show that there are regional differences in the degree of nigral cell loss 
in iPD, MSA, and PSP (Kish et al 1985, Bemheimer et al 1973), visual assessment of 
123I-FP-CIT SPECT imaging in this study could not visualize these differences at the
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level of their striatal neuronal terminals, therefore it was not possible to differentiate 
between iPD, MSA, and PSP. There are several possible explanations for this. 
Postmortem studies tend to include patients with very advanced disease leading to 
biased results. The imaging of the dopamine transporter may be not sensitive enough 
to match the postmortem findings. However postmortem data is clearly not as a useful 
clinical discriminator, although it helps in understanding the pathological nature of 
different parkinsonian syndromes.
The asymmetry index, on the other hand, offers potential for differential diagnosis of
parkinsonism on the basis of greater clinical asymmetry for iPD than other conditions
(Marek et al 1996). Therefore, the asymmetry index was examined in this study as a
potential measure to differentiate iPD from MSA, and PSP. Previous studies have
shown a mixture of results for functional imaging as a technique to differentiate
1 ^between iPD and atypical parkinsonism. I-13-CIT SPECT did not distinguish types 
of parkinsonism in a study of 113 iPD, 9 MSA, and 4 PSP patients (Brucke et al
1997). In another 123I-J3-CIT study, head of caudate uptake showed a greater reduction 
in 5 PSP cases compared to 13 iPD cases, but with significant overlap (Messa et al
1998). Regional striatal 18F-dopa uptake was depressed in a PET study of 16 iPD 
patients, with the most severe involvement in the posterior putamen, compared to a 
uniform severe depression of striatal uptake in 10 PSP patients, and a mixed pattern of 
reduced uptake within the basal ganglia in 18 MSA patients (Brooks et al 1990). 
Subsequent discriminant function analysis refined diagnostic groupings, in particular 
for PSP, but not MSA (Bum et al 1994), and this MSA result was later confirmed in 
another study (Antonini et al 1997). It was found in this study that only putamen 
asymmetry index was significantly lower in parkinsonian syndromes (MSA and PSP)
87
compared to iPD. No difference was found between MSA and PSP. The main 
drawback was the overlap between these groups for an asymmetry index value below 
five. However, only one patient with MSA had a value above five, so that only iPD 
cases had a high asymmetry index. Other ratios such as the SP:NS and P:C ratios were 
not able to differentiate between iPD and MSA or PSP. Obviously there are 
limitations in using this technique to differentiate iPD from other parkinsonian 
syndromes but in selected cases it may provide support to clinical clues suggesting 
that a patient might not have iPD.
1 ftOne of the disadvantages in using F-dopa PET is the necessity to withdraw levodopa 
for a least for 12 hours before scanning. This is usually associated with worsening of 
patients symptoms and causes some difficulties. Imaging dopamine transporters on 
the other hand offer an alternative where patients may not need to stop their main 
dopaminergic medication. Animal studies showed that acute administration of 
levodopa did not interfere with dopamine transporter imaging (Laruelle et al 1993). 
Recently Innis et al (1999) reported no significant effect of levodopa or selegiline on
1 73striatal dopamine transporters using I-13-CIT SPECT. Although there are some 
limitations to their study (patients received therapy for only 6 weeks; small sample 
size was which may result in false negative results) their results add evidence to the 
lack of any significant effect of parkinson’s drug on dopamine transporters. During 
our study patients were maintained on levodopa and/or dopamine agonist medication, 
so this does not have to be withdrawn prior to completion of 123I-FP-CIT SPECT. 
Although selegiline was withdrawn, this may not prove necessary in clinical practice 
in view of the 123I-13-CIT study (Innis et al 1999).
This study confirms the results of previous pre-clinical and clinical studies indicating 
that 123I-FP-CIT appears safe and does not cause significant aberration in laboratory 
values. Adverse events were mostly transient with headache and flu-like symptoms 
the most frequent (Booij et al 1997 b, c 1998 a, 1999, Tissingh et al 1998).
4.5 CONCLUSIONS
1- 123I-FP-CIT SPECT imaging identifies dysfunction of the nigrostriatal 
dopaminergic system even in patients with unilateral iPD.
2- A simple visual assessment of SPECT has a high sensitivity and specificity, thus 
this easily applied diagnostic test has potential utility in confirming the diagnosis in 
patients with parkinsonism and differentiating them from ET and healthy individuals.
3- Although there are limitations of using 123I-FP-CIT SPECT in differentiating iPD 
from atypical parkinsonism (MSA, and PSP), the asymmetry index may be of use in 
certain patients.
4- This study adds evidence to the lack of any true association between iPD and ET.
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CHAPTER 5 
STUDY2
CORRELA TION OF PARKINSON’S DISEASE 
SEVERITY AND DURATION WITH123I-FP-CIT 
SPECT STRIATAL UPTAKE. 
PATTERNS OF DOPAMINE TRANSPORTER 
LOSS IN PARKINSON’S DISEASE, MULTIPLE 
SYSTEM ATROPHY AND PROGRESSIVE 
SUPRANUCLEAR PALSY
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5.1 INTRODUCTION
The classical motor features of iPD (bradykinesia, rigidity, and tremor) usually 
present insidiously and unilaterally then gradually spread contralaterally with a slowly 
deteriorating course (Hoehn and Yahr 1967). These manifestations are attributed 
mostly to dopamine deficit secondary to progressive dopaminergic neuronal 
degeneration in the substantia nigra. Clinical examinations and standard rating scales 
give some indication of the severity of iPD but this is complicated by variability in 
symptoms and signs, rater reliability, and masking effects of drug therapy which are 
only partly overcome by assessing the patient in an “o ff’ state. Therefore, 
development of an objective marker of disease severity is important and could help to 
understand and monitor disease onset, severity and progression.
Although iPD, MSA, and PSP are pathologically different, postmortem studies have 
shown the difficulty in differentiating clinically between these disorders. Of the 100 
cases diagnosed as iPD only 76 was found to fulfil the pathological criteria, while the 
remaining patients were clinically misdiagnosed with PSP and MSA as the diagnosis 
in 11 of the 24 cases without Lewy bodies (Hughes et al 1992).
The aim of this study was to evaluate 123I-FP-CIT as an objective marker of iPD 
severity, which could help to understand and monitor disease onset, severity and 
progression and to assess the relationship between the laterality of parkinsonism
19^features and I-FP-CIT uptake. Also, to evaluate the pattern of loss of dopamine 
transporters in patients with iPD, MSA, and PSP.
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5.2 METHODS
5.2.1 Study Subjects
A subset of patients from Glasgow: Forty one patients with iPD, (33 male, 80%), 
mean age 64 years (SD 9.5), 6 patients with MSA, (4 male, 67%), mean age 63 years 
(SD 6.4), 3 PSP (3 females), mean age 67 (SD 4), and 6 age matched healthy 
volunteers, (3 male, 50%) mean age 63 years (SD 6.1) were included in this study.
A subgroup of 9 iPD cases, with a H&Y score of I were compared with 32 iPD
1 01patients with H&Y score of II-IV and healthy volunteers specifically to assess I-FP- 
CIT uptake in relation to laterality of clinical features.
5.2.2 Study Assessments
Patients were assessed using the UPDRS motor section and H&Y rating scales in an 
“o ff’ phase (Hoehn and Yahr 1967, Fahn et al 1987) by one observer. Standard 
clinical diagnostic criteria were applied for iPD and PS (MSA and PSP) patients as 
described in the study 1 (Chapter 4). Drugs with a potential to interact with striatal 
uptake of 123I-FP-CIT were excluded, as discussed previously.
Components of UPDRS motor score representing lateralised signs for iPD patients 
were scored for right and left limbs, these being items for arm and leg resting and 
action tremor, rigidity, finger taps, hand movements, alternating movements, and leg 
agility. This was designated the unilateral UPDRS, which has a maximum score of 36 
for each side.
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In iPD patients the contralateral striatum was defined as the side opposite to that of 
symptom onset, and for healthy volunteers the contralateral side was arbitrarily 
assigned to the left striatum.
5.2.3 Imaging
In order to minimise the radiation dose, between 1 and 4 hours prior to the
1 9 ^
administration of the I-FP-CIT 120mg of potassium iodide was administered orally 
to each subject to block the uptake within the thyroid of any free iodine in the original 
preparation, or iodine released during the metabolism of the product. Following 123I- 
FP-CIT injection, and where it was considered appropriate, the patient was given two 
further tablets to take between 12 and 24 hours later.
123I-FP-CIT was administered intravenously over a period of approximately 15 
seconds and was followed by a saline flush. The administered activity was in the 
range 111 - 185 MBq in 2.5ml water.
SPECT imaging was performed (i.e. the scan both started and finished) between 3 and 
6 hours after the 123I-FPCIT injection. Ten axial sections, 5mm apart, were considered 
sufficient to cover the striatum, specifically the head of the caudate nucleus and the 
putamen. Each section was acquired in 4 minutes, giving a total scan time of just over 
40 minutes. Total counts acquired were recorded with all per-protocol sections having 
a value greater than 150,000.
SPECT images were acquired using a dedicated multi-detector system (Strichman 
Medical Equipment SME810, Novo Systems, Denmark) linked to an Apple
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Macintosh computer. This sectional scanner acquires sequential single transaxial brain 
sections. The whole brain is imaged using movements of the patient couch. The 12 
individual point-focused radiation detectors move both tangentially and radially such 
that the focal point scans the brain in a "raster" pattern. This unique geometry 
simplifies image reconstruction which is performed by a deconvolution process, and 
resalts in a uniform resolution of approximately 8mm throughout each axial section 
with a slice thickness of 12 mm. Resolution in the longitudinal direction is similar to 
the axial value when a slice spacing of 6mm is used {Figure 5.1).
To account for the absorption of some photons within the brain a linear attenuation 
correction of 85mm (equivalent to as effective attenuation coefficient of 0.117cm'1) 
wai applied based on an automatically detected ellipse matching the outer surface of 
the head. A count dependent filter designed to optimise image resolution and noise 
wai used and set at the "highest" setting provided by the manufacturer. The energy 
wirdow (140-180 keV) was placed symmetrically around the iodine-123 gamma 
energy of 159keV.
5.24 Data Analysis
The images were stored on an Apple Macintosh computer system and data analysis 
wai performed using pre-determined ROI templates. These templates were derived 
fron data on human brain structure available on the "Talairach Daemon" Internet 
wel-site (http://ric.uthscsa.edu/projects/talairachdaemon.html). This site allows 
interactive query and retrieval of a 3-dimensional database of brain structure which 
has as its basis the Co-planar Stereotaxic Atlas of the Human Brain described by 
Takirach and Toumoux in 1988. In parallel with this is a series of overlays (structure
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probability maps) for a number of brain regions including the caudate and putamen. 
These structure probability maps were derived from a large number of Magnetic 
Resonance Imaging (MRI) scans (Collins et al 1995b, Mazziotta et al 1995) and 
delineate the areas within the Atlas window with a fifty-percent probability of being 
associated with each structure or region (Figure 5.2).
Image manipulation software (NIH Image, available from the National Institutes of 
Health at ftp://zippy.nimh.nih.gov/pub/nih-image/) was then used to outline the brain, 
striatal structures and the occipital region (Figure 5.3) for the ROI templates. The 
regions of interest for the left and right putamen were divided into anterior and 
posterior sections at exactly half the anterior-posterior distance. The occipital regions 
were reduced in size to minimise the effects of slice tilt, i.e. if the patient is scanned 
with head tilted backwards the majority of the occipital lobe will appear in the higher 
axial sections and vice versa. Although most of the tilt can be corrected by SPECT 
softw are, reducing the size of the regions ensured that some occipital lobe was present 
even i f  some tilt remained.
An ROI for the outside surface of the head was also determined again using the MRI 
data from the International Consortium for Brain Mapping described in the Talairach 
web-site. In this case the ICBM305 data set an average of 305 normal MRI scans 
were downloaded from the web-site of the Wellcome Department of Cognitive 
Neurology in London (http://www.fil.ion.ucl.ac.uk/spm/) where it is incorporated into 
a software package for statistical analysis of neuroimaging data (Statistical Parametric 
Mapping).
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The standard ROI Templates (right and left caudate, putamen, and occipital) were 
used on the three adjacent sections through the striatum, showing high uptake of 
123I-FP-CIT. It should be noted that the slice separation of the SPECT data was 5 mm 
compared to 4 mm for the Talairach sections. This difference is not thought to be 
significant.
In using the high resolution MRI data in the derivation of ROIs no assumptions are 
made about the ability of SPECT to delineate the same brain structures. On the 
contrary, it is recognised that the poorer resolution of SPECT produces "partial 
volume effects" which means that a proportion of the activity detected within, for 
example, a caudate ROI will originate from outside that region and especially from 
the adjacent anterior putamen. The more correct terms, caudate weighted ROI, 
putamen weighted ROI etc are implied in the names of the ROIs.
The image analysis software supplied with the SPECT scanner was utilised in the 
application of the ROIs to the images. The first part of this process involved the 
identification of the three slices through the striatum. While this is a fairly simple 
procedure when there is normal uptake it is more difficult when the uptake is low, as 
in more advanced iPD, and the ability of the software to re-orientate the images in all 
three orthogonal planes was important. Reference was made to the normal anatomical 
pattern of the striatum (Figure 5.4) where, in the sagittal plane, the caudate curves 
posteriorly and superiorly while the putamen, which lies lateral to the caudate, has 
very little superior projection. Therefore, the first axial section was defined as being 
the most inferior section to show caudate activity thereby ensuring that the body of
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the caudate is not included in the other two sections which might mimic putamen 
uptake.
For each selected SPECT image the ROI template was opened and overlaid on the 
image. The whole template was then scaled to fit the subject's head size to allow for 
inter-individual differences. Individual ROIs were then moved into position with no 
further scaling or rotation allowed. Firstly, the caudate regions were placed such that 
the anterior edge of the ROI corresponded to the anterior edge of the caudate as 
determined visually by the area of highest anterior uptake. The putamen ROIs were 
then positioned immediately posterior to the caudate ROIs as in the original template 
while the separate anterior and posterior putamen regions were moved to the 
appropriate position overlying the whole putamen regions. The occipital ROIs (left 
and right) were allowed minimal movement to avoid areas with low activity, 
presumably due to atrophy in older subjects (Figure 5.5).
All ROI measurements were expressed as mean activity within the region i.e. 
reconstructed counts divided by the area of the region.
19^Measurements of striatal and occipital uptake of I-FP-CIT were then used to derive 
a number of indices of dopamine transporter availability as follows:
Firstly, it was assumed that the detected activity within the striatum consists of ligand 
specifically bound to the transporter site as well as non-specifically bound ligand and 
free ligand. It is also assumed that the non-specific and free components are the same 
in all regions of the brain in which delivery of ligand is similar. Therefore a
97
measurement of uptake in a reference region devoid of specific transporter sites 
allows a correction to be made for the non-specific and free components. The 
occipital cortex was selected as such a region since the density of dopamine 
transporters is known to be negligible there (De Keyser 1989). Specific uptake in 
striatal regions was calculated as: Specific uptake = striatal uptake - occipital uptake.
The ratio of specificrnonspecific uptake, sometimes referred to as the equilibrium 
volume of distribution of the receptor compartment or the binding potential, is 
linearly related to the density of transporters within the region provided equilibrium 
has been achieved at the time of imaging (Laruelle et al 1994). This assumption is 
supported by other studies (Abi-Darghan et al 1996, Booij et al 1999) who showed 
that striatal specific uptake approached a fairly constant level after 3 hours and that 
between 3 and 6 hours the specific: nonspecific ratio was essentially stable. Seibyl et 
al (1998) found a similar plateau but also demonstrated a small decrease in the ratio of
striatal uptake in iPD patients to healthy volunteers during this time window and
• 19*1 
cautioned that this may be due to an overestimation by I-FP-CIT of receptor density
in healthy subjects. Nevertheless, a direct comparison of I-FP-CIT SPECT with
18F-Dopa PET imaging (Ishikawa et al 1996) supported the use of 123I-FP-CIT in the
quantitative assessment of dopaminergic function.
The ratio of the specific uptake in putamen relative to caudate and an asymmetry 
index between hemispheres was therefore calculated.
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A summary of calculated data is as follows:
Parameter
Mean uptake
Calculation
ROI uptake 
ROI area
Specific uptake in striatum Mean striatal ROI uptake - Mean occipital uptake
Specific monspecific ratio 
(SP:NS)
Putamen:caudate ratio 
(P:C)
Asymmetry Index 
(Al)
Specific uptake in striatal ROI 
Mean occipital ROI uptake
Specific uptake in putamen ROI 
Specific uptake in caudate ROI
lOOx (Specific uptake ipsilateral-contralaterali 
0.5x(Specific uptake ipsilateral+contralateral)
Each assessment was carried out for both left and right sides of the brain and the 
analysis compared the data produced for each patient with the stage, severity, and 
duration of disease.
The patterns of striatal uptake was calculated as percentage to normal for the 41 iPD 
patients and compared to 6 MSA and 3 PSP cases.
5.2.5 Statistical analysis
Comparisons of striatal uptake in iPD patients and healthy volunteers were made by 
one-way analysis of variance with Bonferroni correction for multiple comparisons. 
The Wilcoxon signed rank test was used to compare unilateral UPDRS for the onset 
side with that of the non-onset side as well as ipsilateral with contralateral caudate and
193 •putamen uptake. The relationship between I-FP-CIT striatal uptake and staging, 
severity, and disease duration (which was of non-Gaussian distribution) was tested by 
Spearman rank correlation. All tests were two tailed with the accepted level of
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significance p<0.05. Comparisons of striatal uptake in iPD, MSA, PSP and healthy 
volunteers were made by one-way analysis of variance with Bonferroni correction for 
multiple comparisons.
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Figure 5.1 The SPECT imaging: 12 individual point-focused radiation detectors 
move both tangentially and radially such that the focal point scans the brain in a 
’’raster" pattern.
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Figure 5.2 Three adjacent axial sections through the middle of the striatum.
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Figure 5.3 Outline of the brain, striatal structures and the occipital region of interest 
templates obtained using image manipulation software.
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Figure 5.4 Normal anatomical pattern of the striatum where it can be seen that in the 
sagittal plane, the caudate curves posteriorly and superiorly while the putamen, which 
lies lateral to the caudate, has very little superior projection.
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Figure 5.5 Applications of region of interest to SPECT imaging showing right and 
left caudate, putamen and occipital regions, as well as the whole head and the brain.
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5.3 RESULTS
Twenty seven iPD patients had right sided onset and 14 had left sided onset. The 
H&Y score was I in 9 cases, II in 16 cases, III in 11 cases, IV in 5 cases. The mean 
duiration of illness was 7.2 years (Cl 5.1-9.3). The median UPDRS motor score for 
iPD was 23 (inter-quartile range 17-36) (mean 28, SD17). Median UPDRS for MSA 
wais 60 (inter-quartile range 50-63) (mean 53, SD17), H&Y score was II in one case, 
III in one case, IV in one case and V in 3 cases, with mean duration of illness 5.8 
years (SD 2.2). The three cases of PSP, mean was 37 (SD 18) (median and inter­
quartile range not appropriate), H&Y score was III in two cases and IV in one case, 
wilth mean duration of illness of 3.3 years (SD 2.5).
Specific:nonspecific ratios in idiopathic Parkinson’s disease and healthy volunteers 
and correlation with unilateral UPDRS
Ipsilateral and contralateral putamen SP:NS ratios were significantly reduced 
(p<0.001) for both H&Y I and H&Y II-V, compared to healthy volunteers (Table 5.1, 
Figure 5.6), as were the corresponding values for the caudate (Table 5.1).
Unilateral UPDRS showed a significantly higher score on the side of symptom onset 
compared to the non-onset side for both H&Y I, [onset side 7 (3.5-11.5); non-onset 
side 0.0 (0-0.5)] (Figure 5.6 A) and for H&Y II-V, [onset side 27.5 (21-45); non-onset 
side 7.5 (4.25-14)] (Figure 5 .6B).
Compared to this the difference between ipsilateral and contralateral caudate SP:NS 
ratio as well as the corresponding values for the putamen were statistically significant
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for both groups of iPD patients, although there was overlap of the reading between 
groups (Table 5.1, Figure 5.6).
No significant difference was found between ipsilateral and contralateral SP:NS ratio 
in caudate or putamen for healthy volunteers (Table 5.1, Figure 5.6).
There was a correlation between ipsilateral and contralateral caudate and putamen 
SP:NS ratios and unilateral UPDRS (Table 5.2).
Correlation o f  motor scores and specific: nonspecific ratios
H&Y stage and UPDRS motor score were significantly correlated with mean striatum, 
caudate and putamen SP:NS ratios (Table 5.3, Figure 5.7). There was also a 
significant correlation between both H&Y stage and UPDRS motor score and 
ipsilateral as well as contralateral caudate and putamen uptake ratios (Table 5.3). A 
good correlation was also found between the bradykinesia component of UPDRS and 
striatum, caudate and putamen SP:NS but rigidity and tremor were poorly correlated 
with these values (Table 5.3).
Correlation o f disease duration and specific .nonspecific ratios 
The duration of iPD was significantly correlated with mean striatum, caudate and 
putamen SP:NS ratios, as well as ipsilateral and contralateral values (Table 5.3, 
Figure 5.8).
Putamen:caudate ratios
There were significant differences in P:C ratio between unilateral (H&Y I) and 
bilateral (H&Y II-IV) iPD patients compared to healthy volunteers (p<0.001)
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(Table 5.4). Correlation with disease stage, UPDRS components and duration was 
generally poorer than for SP:NS ratios, although the tendency was for the ratio to 
decrease as the disease progressed (Table 5.5).
Asymmetry indices
There were significant differences between putamen Asymmetry index in unilateral 
(H&Y I) iPD patients and healthy volunteers (p<0.001) but no significant differences 
were found for caudate asymmetry index (Table 5.4). However, there were no 
significant differences in caudate or putamen asymmetry index between bilateral 
(H&Y II-IV) iPD patients compared to healthy volunteers (p>0.05) (Table 5.4). 
Asymmetry index did not correlate with duration of the disease but the putamen 
asymmetry index did show some correlation with disease stage and severity (Table 
5.6).
The pattern o f the striatal uptake in Parkinson’s disease, multiple system atrophy, 
progressive supranuclear palsy and healthy volunteers
The mean caudate and putamen SP:NS ratio was significantly lower in iPD, MSA, 
and PSP patients compared to healthy controls (p<0.001) (Table 5.7).
The mean putamen SP:NS ratio was significantly reduced compared to caudate in iPD 
and the posterior putamen ratio also was significantly lower than anterior putamen 
(p<0.001).
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The posterior putamen SP:NS ratio in healthy volunteers was significantly lower than 
anterior putamen uptake (pO.OOl). Caudate and putamen ratios were not significantly 
different.
The mean caudate SP:NS ratios were depressed in a similar level for each subgroup of 
parkinsonian patients: iPD patients it was 50% of normal, for MSA it was 44% of 
normal and for PSP it was 50% of normal. Tracer uptake was severely depressed in 
the putamen, 29% of normal for iPD, 25% for MSA and 24% for PSP. Anterior 
putamen uptake was reduced by 31% in iPD, 28% in MSA, and by 28.5% in PSP. 
Posterior putamen uptake was reduced to 19% of normal for iPD, 18% for MSA, and 
10% in PSP. No significant differences between caudate, anterior putamen and 
posterior putamen uptake were found between iPD, MSA, PSP.
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Table 5.1 Difference between ipsilateral and contralateral uptake for both caudate and 
putamen in 9 unilateral, and 32 bilateral idiopathic Parkinson’s disease patients, and 6
healthy volunteers.
Caudate Putamen
Ipsi Contra p value Ipsi Contra p value
H&Y I 2.1 1.8 0.02 1.3 0.90 0.008
(1.6-2.6) (1.4-2.2) (1.0-1.7) (0.73-1.1)
H&Y II-V 1.6 1.4 <0.0001 0.91 0.76 <0.0001
(1.3-1.9) (1.1-1.9) (0.70-1.1) (0.55-0.97)
Healthy volunteers 3.5 3.5 0.62 3.1 3.1 0.43
(3.1-3.8) (3.1-4.0) (3.0-3.3) (2.8-3.4)
Data are mean (95% confidence interval) 
Ipsi = ipsilateral 
Contra = contralateral
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1 9 ^Table 5.2 Correlation coefficients (Spearman rank correlation) for I-FP-CIT 
SPECT measures and unilateral UPDRS in idiopathic Parkinson’s disease.
Specific:nonspecific uptake ratio
Ipsi Contra Ipsi Contra
caudate caudate putamen putamen
Unilateral UPDRS -0.34 -0.36 -0.44 -0.39
(onset side) p value 0.027 0.021 0.003 0.012
Unilateral UPDRS -0.47 -0.47 -0.43 -0.56
(non-onset side) p value 0.001 0.001 0.005 0.0001
UPDRS = Unified Parkinson’s Disease Rating Scale 
Ipsi =  ipsilateral 
Contra =  contralateral
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Table 5.4 Asymmetry index and putamen:caudate ratio in 9 unilateral and 
32 bilateral Parkinson’s disease patients, and 6 healthy volunteers.
Asymmetry index Putamen:caudate ratio
Caudate Putamen Ipsilateral Contralateral
H&Y I 16** 37* 0.63* 0.51*
(6.7,25) (19,56) (0.58,0.68) (0.44,0.57)
H&Y II-V 14** 16** 0.56* 0.52*
(7,20) (7.8,24) (0.51,0.60) (0.45,0.58)
Healthy volunteers -1.3 0.85 0.90 0.88
(-7.3,4.6) (-6.6,8.3) (0.83,0.98) (0.86,0.91)
* p <0.001 compared to healthy volunteers 
**P>0.05 compared to healthy volunteers 
Data are mean (95% confidence interval)
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Table 5.5 Correlation coefficients (Spearman rank correlation) for putamen:caudate 
ratio of 123I-FP-CIT striatal uptake and UPDRS motor scoring and duration of illness 
in 41 idiopathic Parkinson’s disease patients.
Putamen:caudate ratio
Ipsi Contra Mean
Disease stage H&Y 
p value
-0.38
0.01
-0.17
0.28
-0.27
0.09
Disease severity score UPDRS 
p value
-0.37
0.01
-0.14
0.37
0.29
0.07
Bradykinesia 
p value
-0.34
0.03
-0.14
0.37
-0.29
0.07
Rigidity 
p value
-0.15
0.33
-0.18
0.26
-0.07
0.65
Tremor 
p value
-0.26
0.09
-0.03
0.84
-0.30
0.06
Duration
p value
-0.42
0.007
-0.12
0.46
-0.34
0.01
H&Y  =  Hoehn and Yahr
UPDRS =  Unified Parkinson’s Disease Rating Scale 
Ipsi = ipsilateral 
Contra =  contralateral
119
Table 5.6 Correlation coefficients (Spearman rank correlation) for Asymmetry index 
1of I-FP-CIT striatal uptake and UPDRS motor scoring and duration of illness in 41 
idiopathic Parkinson’s disease patients.
Asymmetry index 
Caudate Putamen
Disease stage H&Y 0.00 -0.43
p value 0.97 0.005
Disease severity score UPDRS -0.03 -0.42
p value 0.82 0.006
Bradykinesia 0.00 -0.34
p value 0.9 0.03
Rigidity -0.11 -0.35
p value 0.49 0.02
Tremor -0.01 -0.2
p value 0.94 0.19
Duration -0.21 -0.09
p value 0.19 0.56
H&Y  =  Hoehn and Yahr
UPDRS =  Unified Parkinson’s Disease Rating Scale
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Table 5.7 The mean specificinonspecific uptake in idiopathic Parkinson’s disease 
(41), multiple system atrophy (6), progressive supranuclear palsy (3), and controls (6).
Caudate Whole
Putamen
Anterior
putamen
Posterior
putamen
Idiopathic Parkinson’s 1.6 0.90 1.1 0.48
disease (1.4-1.8) (0.73-1.l)a (0.92-1.3) (0.34-0.62)b
Multiple system 1.4 0.79 0.98 0.45
atrophy (0.73-2.1) (0.37-1.2) (0.48-1.5) (0.14-0.77)
Progressive 1.6 0.76 1.0 0.27
supranuclear palsy (0.54-2.6) (0.13-1.4) (0.27-1.8) (-0.05-0.59)
Healthy controls 3.5 3.1 3.5 2.5
(3.1-3.9) (2.9-3.3)c (3.1-3.9) (2.3-2.7)d
a  p<0.001 compared to caudate in Parkinson’s disease 
bp<0.001 compared to anterior putamen in Parkinson’s disease 
°p>0.05 compared to caudate o f  controls 
dp<0.001 compared to anterior putamen o f controls
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Figure 5.6 Putamen specific:nonspecific ratio compared to unilateral UPDRS scores 
in 41 idiopathic Parkinson’s disease patients and 6 healthy volunteers.
Putamen uptake was reduced in idiopathic Parkinson’s disease patients to less than 
half the level in healthy volunteers, and there was an overlap between putamen uptake 
of onset and non-onset sides for H&Y I and H&Y II-V patients.
A) Results for H&Y grade I (n=9) patients. There was a significantly higher motor 
score in the onset side unilateral UPDRS compared to non-onset side (p=0.004).
B) Results for H&Y grade II-IV (n=32) patients. Unilateral UPDRS was higher in 
onset than non-onset side (p<0.0001).
Data are mean and 95% confidence interval for putamen uptake, and median and 
inter-quartile range for unilateral UPDRS.
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Figure 5.7  Correlation of Unified Parkinson’s Disease Rating Scale motor score with 
mean putamen specific:nonspecific uptake ratio in 41 patients with idiopathic 
Parkinson’s disease. One patient with an outlying observation (ratio 3.38, UPDRS 42, 
is not shown, but is included in statistical analysis). Regression line shown with 95% 
confidence limits.
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Figure 5.8 Correlation of duration of disease in 41 idiopathic Parkinson’s disease 
patients with mean putamen specific:nonspecific uptake ratio. One patient with an 
outlying observation (ratio 3.38, UPDRS 42, is not shown, but is included in statistical 
analysis). Regression line shown with 95% confidence limits.
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5.4 DISCUSSION
A significant relationship between global severity of iPD and functional imaging has 
previously been shown for 18F-dopa PET and 1231-P -CIT studies (Morrish et al 1996, 
Seibyl et al 1995, Brucke et al 1997). Morrish et al (1996) in a 18F-dopa study showed 
a correlation between UPDRS motor score and mean striatum and putamen uptake, 
but not caudate uptake. Seibyl et al (1995) using 123I-p-CIT SPECT demonstrated a 
correlation between both stage and severity of iPD and ipsilateral and contralateral 
caudate and putamen ratios. In two previous 123I-FP-CIT studies no such correlation 
was shown (Booij et al 1997c, Tissingh et al 1998), but Ishikawa et al (1996) showed 
a correlation between striatal:occipital ratios and UPDRS motor score for H&Y I and
1 91II patients. Our results confirm this prior observation for I-FP-CIT in early disease 
(H&Y I) but also extend it to later disease (H&Y II-V) showing a good correlation 
between the stage and severity of iPD and the decline in mean striatum, caudate and 
putamen SP:NS ratios as well as ipsilateral and contralateral striatum, caudate and 
putamen SP:NS. Further correlation was found between the striatum, caudate and
1 9 1putamen SP:NS ratios and disease duration. These findings imply that I-FP-CIT has 
a similar capacity to PET and I-p-CIT in monitoring severity and progression of 
iPD.
We examined the relationship between 123I-FP-CIT and differing clinical features of 
parkinsonism, in light of previous reports suggesting a better correlation with
bradykinesia than with tremor (Seibyl et al 1995, Brucke et al 1997). Our results for
1 ^
I-FP-CIT matched these findings, and also showed a poor correlation with rigidity 
contrary to the finding for 123I-p-CIT SPECT (Brucke et al 1997). However the 
degree of correlation reported by Brucke et al (1997) was also poor (r=-0.38). Seibyl
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et al (1995) suggested that the greater weighting for bradykinesia compared to tremor 
within UPDRS is responsible for this correlation difference. However, in the current 
study rigidity and tremor showed a similarly poor correlation with SP:NP ratios 
(r=-0.3) even though rigidity is less represented in the UPDRS motor scale than 
tremor. A number of clinical observations support the notion that tremor origin could 
differ from bradykinesia, namely the slow progression of benign tremulous 
Parkinson’s disease (Quinn 1995), the better response of bradykinesia and rigidity to 
dopamine replacement compared to tremor, and the improvement of tremor but not 
other symptoms by thalamotomy. Thus tremor severity may be linked to thalamic 
circuitry which is not assessed by 123I-FP-CIT SPECT techniques. Others have also 
considered the possibility that tremor is not directly related to loss of dopamine 
neurones (Brucke et al 1997).
Less attention has been paid to the relationship between the laterality of symptoms 
and signs and functional imaging results. For example Seibyl et al (1995) found a 
significant correlation between global UPDRS and right and left basal ganglia uptake, 
and their finding was confirmed by another study (Brucke et al 1997). In one study 
using n C-nomifensine and 18F-dopa PET in 9 iPD cases, Leenders et al (1990) 
showed a correlation between percent side-to-side differences in clinical score and 
percent side-to-side differences in putamen uptake, but no correlation was found 
between global clinical severity and mean specific putamen uptake. It is worth noting 
that Leenders et al (1990) used bradykinesia and rigidity scoring and omitted tremor, 
as their study preceded the universal adoption of UPDRS. Our comparison of 
unilateral motor features against contralateral striatal uptake ratios provides an 
important new message about the relationship between clinical and SPECT results.
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Our finding of a significantly higher unilateral UPDRS in the onset side, for both H& 
Y I and H&Y II-V is of course consistent with clinical practice observation of 
invariably unilateral onset of iPD and persistence of worse symptoms in the onset side 
long after the disease becomes clinically bilateral (Lee et al 1995). The finding of a 
difference between ipsilateral and contralateral striatal uptake with the contralateral
j  side being more severely affected is therefore expected (Wenning et al 1998).
!
J  However, the significant overlap in the range of striatal uptakes between the
I
ipsilateral and contralateral side, which occurs in the absence of any overlap in 
UPDRS values, may be an indication that other factors may contribute to the severity 
and the laterality of the clinical findings. For example, the degenerative process in the 
basal ganglia may start in one side and due to dopaminergic interdependence between 
the two nigrostriatal systems the degeneration on the other side becomes similar, but 
with a slight difference causing significant clinical asymmetry. This is in agreement 
with animal model data which showed that unilateral lesioning in the substantia nigra 
can cause bilateral striatal dopamine depletion (Cheramy et al 1981, Lawler et al 
1995). It is supported by Doder et al (1999) who described a patient with 
parkinsonism as a result of unilateral striatal lesion due to head injury as shown by 
MRI, but with 18F-dopa PET indicating bilateral striatal impairment. Another 
explanation could relate to prior observations that a given level of basal ganglia 
activity is associated with a variable range of clinical severity between patients 
(Seibyl et al 1995, Brucke et al 1997); our results suggest that this variable clinical 
involvement may also be present within individual patients, and between the basal 
ganglia of each brain hemisphere. Factors other than nigrostriatal degeneration such 
as abnormalities in the thalamic or subthalamic circuitry, not visualised by the SPECT 
technique may contribute to disease severity. Finally, imaging of the dopamine
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transporters may not be as sensitive as clinical measures, although this concept is not 
well supported from global scoring and imaging data in this and other reports.
In our study P:C ratios distinguished iPD patients (both H&Y I and H&Y II-IV) from 
healthy volunteers while only putamen Al was able to do so for unilateral iPD (H&Y 
I) patients. There was a poor correlation for disease staging, severity and duration 
with P:C ratios and Al compared to SP:NS. Also, caudate and putamen Al did not 
differentiate bilateral iPD (H&Y II-IV) from healthy volunteers even although SP:NS 
ratios clearly separated bilateral iPD from healthy volunteers. However, the Al and 
P:C ratio were able to distinguish parkinsonism from ET and healthy volunteers. 
Further, poor correlation for iPD staging, severity or duration with either P:C ratio or 
asymmetry index was found. Putamen asymmetry index tended to correlate better 
with H&Y stage and disease severity as assessed by UPDRS, and even better 
correlation was found with disease duration. Accordingly, SP:NS is the most useful 
measure, as suggested by other studies (Marek et al 1996).
The pattern of involvement in the basal ganglia in our study was similar to a previous 
PET study (Brooks et al 1990, Ilgin et al 1999), as well as 123I-p-CIT SPECT (Brucke 
et al 1997, Messa et al 1998) and postmortem studies (Kish et al 1985). Putamen was 
more severely affected than caudate, and the posterior part of putamen more affected 
than the anterior part. The explanation suggested by previous studies is that the 
ventrolateral part of the nigral cells, which project into posterior putamen is mostly 
affected in iPD due to relatively lower melanin in these cells, which could protect 
against free radical damage ((Bemheimer et al 1973, Goto et al 1989, German et al 
1989, Gibb et al 1990b, Brooks et al 1990). Our interesting finding however of
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significantly lower dopamine transporters in the posterior putamen of healthy people 
suggests that the nigrostriatal projection in posterior putamen has a relatively reduced 
level of dopamine transporters compared to the anterior putamen and caudate and this 
could be another explanation of the vulnerability of posterior putamen to Lewy body
i
degeneration.
This study showed that the loss of dopamine transporters was 50% in iPD patients for 
the caudate and 70% for the putamen compared to normal volunteers, contrary to 
much higher figures from postmortem studies. Kaufman and Madras (1991) showed 
80% reduction in the dopamine transporter density in the caudate and 96% in the 
putamen of 8 patients with iPD compared to 6 control brains. These results were 
confirmed by another postmortem study (Niznik et al 1991) and parallel the reduction 
of dopamine in the striatum (Kish et al 1988). The mismatch between our 123I-FP-CIT 
SPECT results and the postmortem studies is probably because pathological studies 
examine severe terminal disease.
Our study showed different degrees of severity in the involvement of caudate and 
putamen from a previous 18F-dopa PET study in which a reduction to 17% in the 
caudate activity, 40% in anterior putamen, and 60% in posterior putamen in iPD was 
found (Brooks et al 1990). These values are much lower than in our study (50% in 
caudate, 69% in anterior putamen and 81% in posterior putamen). However, our 
results are in agreement with previous PET imaging of the dopamine transporters 
using [11C]-WIN 35,428 (Ilgin et al 1999). The difference in results between imaging
1 f> 1 o
the dopamine transporters and F-dopa PET could be due to the fact that F-dopa 
uptake does not reflect a direct measure of dopamine but reflects aromatic amino acid
133
decarboxylase activity (Brooks et al 1990), which has been shown to fall to 88% of 
normal in the caudate and 37% of normal in the putamen in postmortem studies 
(Nagatsus et al 1979). On the other hand dopamine transporters tend to be reduced in 
parallel with dopamine in iPD (Kaufman et al 1991), which was reduced to 10% of the 
normal level when measured in postmortem subjects (Javoy-Agid et al 1986). Recent 
animal studies show that the change in dopamine transporters reflect more accurately 
the degree of neuronal loss than the levodopa levels which tend to underestimate the 
decrease in dopaminergic neurones (Ito et al 1999). This makes imaging of dopamine 
transporters with PET or SPECT more appropriate in detecting the loss of 
dopaminergic neurones.
Brooks et al (1990) reported similar reductions in putamen uptake in iPD, MSA and 
PSP, using striatal 18F-dopa uptake, with PSP patients having a severe reduction in 
caudate ard the putamen and iPD patients having significant sparing of caudate 
function. Patients with MSA showed a mixed pattern with resemblance to iPD in 
some features and to PSP in others. Also, they reported a similar degree of reduction 
in the posterior putamen of all three groups of patients with anterior putamen as 
severely involved as posterior putamen in PSP but not in iPD. Again MSA patients 
showed a nixed pattern. Ilgin et al (1999), using [11C]-WIN35,428 PET to image 
dopamine transporters, confirmed the uniform degree of the involvement of the 
caudate ani putamen in PSP but found more profound loss of dopamine transporter in 
the posterior putamen of iPD patients. 123I-P-CIT SPECT studies showed mixed 
results witl Messa et al (1998) reporting a significant reduction of caudate uptake in 
PSP compired to iPD and Brucke et al (1997) reporting no differences between iPD, 
MSA, and PSP. Our study however showed that the pattern of the reduction of
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dopamine transporters in the caudate, anterior putamen and posterior putamen in iPD, 
MSA, PSP was similar with no significant differences but with tendency of posterior 
putamen to be more affected than the anterior putamen. It should be noted that in 
some of the above studies, even though there were differences between iPD and PSP, 
the uptake values showed overlap. Therefore using the pattern of distribution of tracer 
uptake as a tool in differentiating iPD from atypical parkinsonism is of limited use in 
individual patients in clinical practice.
5.5 CONCLUSIONS
1- This study shows that uptake of 123I-FP-CIT differentiates iPD patients, and in 
particular unilaterally staged iPD, from healthy volunteers.
2- Uptake ratios correlated with staging, severity, and duration of disease, matching 
previous PET and 123I-p-CIT reports.
3- The degree of asymmetry of I-FP-CIT binding uptake is not as marked as the 
clinical asymmetry suggesting that factors other than nigrostriatal degeneration may 
contribute to disease severity.
4- While bradykinesia was correlated with I-FP-CIT, tremor was not, and this 
supports the idea of an origin for tremor outwith the dopamine transporter system.
5- This study showed that the number of dopamine transporters is significantly lower 
in posterior putamen than anterior putamen in healthy volunteers, which could explain 
the well known fact of greater vulnerability of the posterior putamen to degeneration 
than other parts of the striatum in iPD. A similar pattern of dopamine transporters loss 
was found in iPD, MSA and PSP, therefore using striatal pattern distribution of 
dopamine transporters is of limited use in differentiating iPD from atypical 
parkinsonism.
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6- The wide availability of SPECT and the fast kinetics of 123I-FP-CIT make it an 
ideal technique to define nigrostriatal change in iPD, with significant potential in 
monitoring disease progression and putative neuroprotective therapy.
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CHAPTER 6 
STUDY 3
123I-FP-CIT SPECT STRIA TAL UPTAKE IN  
TREMOR DISORDERS
137
6.1 INTRODUCTION
Bradykinesia, rigidity and resting tremor remain the standard features to diagnose 
iPD. However, these symptoms and signs can be subtle in the early stages of the 
disease reducing the level of certainty about the diagnosis, therefore delaying 
confirmation of the diagnosis. Also, the prevalence of subtle extrapyramidal signs in
I elderly subjects without a known neurological disease is 30% to 35% which could add
|
j  to the problems of diagnosing parkinsonism (Richards et al 1993, Bennett et al 1996).
i
\
The presymptomatic phase of parkinsonism is well recognised, but its duration 
debatable. Some authors suggested up to 40-50 years (Koller 1992, Vingerhoets et al 
1994), while others argued that the presymptomatic stage could be as short as 3-5 
years (Feamley and Lees 1991, Morrish et al 1996, 1998). Thus detecting nigrostriatal 
degeneration by functional neuroimaging in patients with very early symptoms and 
signs not yet fulfilling any diagnostic criteria would help in confirming parkinsonism, 
avoiding unnecessary delay in addressing the issue of prognosis with patients. This 
could also have significant implications if neuroprotective treatment becomes 
available in the future.
The aim of this study is to examine the potential of using 123I-FP-CIT SPECT to 
detect nigrostriatal degeneration in patients with tremor disorders, not fulfilling 
standard diagnostic criteria.
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6.2 METHODS
6.2.1 Study Subjects
Patients with tremor (either sex, within an age range of 40-80 years) not fulfilling 
either step 1 UK Brain Bank criteria for iPD (bradykinesia and rigidity and/or tremor) 
(Gibb et al 1988), or Findley and Koller (1994) criteria for definite or probable ET, 
were recruited. They were compared to 9 patients with iPD (H&Y I) diagnosed 
according to UK Brain Bank criteria (these 9 patients are the Glasgow cases from 
study 1, chapter 4; out of a total of 23 per-protocol cases scoring H&Y I), and were 
also compared to six healthy volunteers who were also Glasgow cases from the 
previous study.
Patients with clinical features suggestive of MSA, PSP, cerebrovascular disease, 
dementia, head injury or encephalitis were excluded. Also patients with causes of 
enhanced physiological tremor including hyperthyroidism, exposure to tremorogenic 
drugs, possible psychogenic tremor, or with any evidence of sudden onset or stepwise 
deterioration were excluded. Any drug intake with the potential to interact with 
striatal uptake of 123I-FP-CIT by the dopamine transporter was disallowed, as 
discussed in study 1 (Chapter 4).
6.2.2 Study Assessments
Patients gave written informed consent and the study was approved by the Ethics 
Committee in Southern General Hospital and by the Administration of Radioactive 
Substances Advisory Committee. Standard safety assessments (vital signs, physical 
examination, laboratory tests) were conducted at baseline and repeated at least twice 
during the study period.
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; In tremor and iPD patients the contralateral (symptomatic) striatum was defined as the
i
side opposite to that of symptom onset and for healthy volunteers the contralateral 
side was arbitrarily assigned to the left striatum.
6.2.3 Imaging
I
The patients underwent the similar imaging procedures as described in the methods 
section in study 2 (Chapter 5).
i
6.2.4 Data Analysis
Visual assessment of 123I-FP-CIT SPECT consisted of the institutional read only and a 
consensus blinded read was not performed. The SPECT scans were graded as normal 
and abnormal, which was graded further to abnormal grade 1, abnormal grade 2, and 
abnormal grade 3 (for full detailed definition see the method section of the study 1, 
Chapter 4). Striatal specificmonspecific ratios analysis was performed according to 
the methods described in study 2 (Chapter 5).
6.3 RESULTS
6.3.1 Study Populations
Ten patients with tremor (6 male, 60%), mean age 60 years (SD 6.6), were compared 
to 9 patients with iPD (8 male, 89%), mean age 56 years (SD 9.9) with H&Y I, and 6 
healthy volunteers, (3 male, 50%) mean age 63 years (SD 6.1). All tremor patients 
were H&Y grade I. Clinical features of patients with tremor are summarised in Tables
6.1 and 6.2.
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6.3.2 Visual Assessments
Of the 10 patients with tremor, 6 had abnormal visual 123I-FP-CIT SPECT scans, 
while 3 (cases 6, 9 and 10) had a normal scan reading. All iPD patients (H&Y 1) had 
abnormal scan, while all healthy volunteers had normal scans (Table 6.3, Figure 6.1).
6.3.3 Specific:nonspecific Ratios
Four of the ten tremor patients (cases 1, 3, 7 and 8) had specific:nonspecific ratios for
j
| caudate and putamen within the range for patients with iPD fulfilling diagnostic 
criteria. All of these patients had an abnormal visual scan assessment. Cases 6, 9 and 
10 had ratios within the normal range and this matched a normal visual assessment in 
each case. The remaining three cases (2, 4 and 5) showed reduced ratios but these 
were outwith the iPD range; the duration of disease in these 3 patients matched that of 
iPD patients fulfilling diagnostic criteria. Each of these cases had an abnormal visual 
scan assessment (Table 6.4, Figures 6.1,6.2,6.3).
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Table 6.3 123I-FP-CIT institutional read results in tremor patients, idiopathic
Parkinson’s disease and healthy volunteers.
Normal Abnormal
Grade 1 Grade 2 Grade 3
Tremor patients 
(n=10) 3 4 2 1
Idiopathic Parkinson’s disease 
(n=9)
0 3 5 1
Healthy volunteers 
(n=6)
6 0 0 0
Normal (grade 0): Symmetrical uptake in both right and left caudate and putamen. 
Abnormal (grade 1): Uptake is symmetrical with almost normal or reduced putamen 
activity in one hemisphere and a more marked change on the other side.
Abnormal (grade 2): Uptake is significantly reduced in the putamen on both the right 
and left sides.
Abnormal (grade 3): Uptake is virtually absent from both putamen and caudate nuclei 
on each side.
For more detailed definition o f abnormal scan types, see methods section in study 1, 
(chapter 4).
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Table 6.4 A) Specific:nonspecific 123I-FP-CIT uptake ratios in ten patients with
tremor.
Patient
num ber Caudate Putamen
Ipsi Contra Mean Ipsi Contra Mean
1 2.46 2.01A 2.23A 1.49A 1.25A 1.37A
2 3.27* 2.64 2.95 2.56 1.41 1.99
3 2.45 2.12A 2.33A 1.38A 0.92A 1.15A
4 3.70* 3.33* 3.52* 2.31 1.81 2.06
5 3.41* 3.83* 3.62* 2.31 2.17 2.24
6 3.36* 3.74* 3.55* 3.18* 3.32* 3.25*
7 2.68 1.99A 2.34 1.86 1.11A 1.48
8 1.57A 1.39A
<00 0.88A 0.96A 0.92A
9 3.80* 3.82* 3.81* 3.31* 3.26* 3.29*
10 4.47* 4.51* 4.49* 4.33* 4.50* 4.42*
Ipsi-ipsilateral, contra-contralateral
*  Within normal range, A within parkinsonian range, the other values lie between 
normal and parkinsonian range
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Table 6.4 B) Specific:nonspecific 123I-FP-CIT uptake ratios in idiopathic Parkinson’s
disease patients (n=9) and healthy volunteers (n=6).
Caudate Putamen
Ipsi Contra Mean Ipsi Contra Mean
Idiopathic 
Parkinson’s 
disease 
(H&Y I)
2.1 
(1.6-2.6)
1.8
(1.4-2.2)
2.0
(1.5-2.4)
1.3
(1.0-1.7)
0.90
(0.73-1.1)
1.1
(0.88-1.4)
Healthy
volunteers
3.5
(3.1-3.8)
3.5
(3.1-4.0)
3.5
(3.1-3.9)
3.1
(3.0-3.3)
3.1
(2.8-3.4)
3.1
(2.9-3.3)
Data are mean (Cl)
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Figure 6.1 123I-FP-CIT uptake in 10 tremor patients.
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Figure 6.2 Specific:nonspecific ratios in 10 patients with tremor, 9 idiopathic
Parkinson’s disease cases, and 6 healthy volunteers.
A) Caudate specificinonspecific ratios showing reduced uptake in the asymptomatic 
side of 4 of 10 patients with tremor (inverted solid triangle) and 8 of 9 patients with 
idiopathic Parkinson’s disease (inverted solid triangle). In the symptomatic side 5 
tremor patients had reduced uptake (hollow triangle) and the other 5 had uptake 
within normal range (hollow triangle); all idiopathic Parkinson’s disease patients had 
abnormal uptake (hollow triangle).
B) Putamen specific:nonspecific ratios showing reduced uptake in the asymptomatic 
side in 7 of 10 tremor patients (inverted solid triangle). Three patients had a reduced 
specific :nonspecific ratio but outwith the uptake of patients fulfilling diagnostic 
criteria for idiopathic Parkinson’s disease (inverted solid triangle). Findings were 
similar in the symptomatic side (hollow triangle). All idiopathic Parkinson’s disease 
had reduced uptake bilaterally (hollow triangle).
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Figure 6.3 Correlation of duration of disease in idiopathic Parkinson’s disease (41 
cases) with mean putamen specific:nonspecific uptake ratio (study 2, chapter 5) and 
10 patients with tremor. Three of the tremor patients have reduced uptake (green solid 
triangles, cases with putamen uptake of 1.99, 2.06 and 2.24) outwith the parkinsonian 
range but a similar duration of disease to cases with idiopathic Parkinson’s disease 
fulfilling diagnostic criteria.
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6.4 DISCUSSION
The clinical features of parkinsonism have been scored for sensitivity and specificity 
for diagnosing iPD in several studies. Hughes et al (1992), on the basis of a clinico- 
pathological study, estimated that the presence of 2 of the cardinal features of 
parkinsonism gives a 99% sensitivity but only 9% specificity. Also they estimated that 
the presence of the three features reduces the sensitivity to 65% but increases the 
specificity to 71%. On the other hand isolated resting tremor has a sensitivity of 76% 
and specificity of 50%. Therefore at best clinical features provides a specificity of 
70%. However, Brooks et al (1992b) using 18F-dopa PET showed that the presence of 
resting tremor, reduced arm swing, cogwheel rigidity, and short tremor duration in 
patients with predominantly postural tremor does not always predict an abnormality of 
the nigrostriatal system. ET patients may exhibit mild signs suggesting parkinsonism 
such as a slightly expressionless face and a stooped posture especially in the elderly 
(Deuschl et al 1998a). Also, applying UK Brain Bank criteria improves the diagnostic 
accuracy of iPD from 76% to 82% (Hughes et al 1992). Thus relying on neurological 
examination and applying diagnostic criteria alone can be misleading in the diagnosis 
of iPD and ET. Also, it may take many years before all the clinical features emerge to 
make the clinical diagnosis relatively easy.
In the above mentioned 18F-dopa PET study, Brooks et al (1992b) found that some 
patients with rest tremor and without bradykinesia, therefore not fulfilling UK brain 
bank criteria for iPD, have disruption of the nigrostriatal dopaminergic system while 
other patients with predominant postural tremor, who fail Findley and Koller criteria 
for definite ET, have a normal nigrostriatal system. However, one patient with 
sporadic postural tremor had a putamen uptake compatible with iPD, and
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subsequently developed features of the disease, while another patient had abnormal 
putamen uptake but not severe enough to be classified as iPD and with clinical 
features remaining static after 2 years of follow-up. In patients with resting tremor 9 
had contralateral and 8 ipsilateral reduction of putamen uptake compatible with iPD. 
Further evidence that tremor characteristics and other clinical features do not 
discriminate these conditions comes from Asenbaum et al (1998) who reported 
normal 123I-J3-CIT uptake in 32 patients with ET compared to iPD. They classified 
their ET patients into 3 groups, definite, probable and possible, and more than half 
exhibited resting tremor as well as the usual postural tremor. Patients with 
neurological signs additional to tremor such as lack of arm swing were however 
excluded from the possible ET group. Therefore, using functional neuroimaging in 
patients with atypical tremor could help in clarifying diagnosis.
One of the potential uses of 123I-FP-CIT is to detect nigrostriatal degeneration in 
patients with predominant tremor who have mild and early symptoms, and subtle 
signs. In the present study none of the 10 patients fulfilled standard diagnostic clinical 
criteria and all had mild symptoms making performance and interpretation of a 
challenge test difficult. In all but three 123I-FP-CIT SPECT was abnormal indicating 
disruption of the nigrostriatal pathway. Cases 6 and 9 both of whom had unilateral 
postural and action tremor, and in whom a diagnosis of iPD could not be excluded 
clinically at this stage, showed a normal scan which on present evidence is against the 
possibility of parkinsonism. A further three of the tremor patients had reduced striatal 
uptake but above the iPD range of uptake, although the duration of their symptoms 
matched cases fulfilling diagnostic criteria. It seems likely that these patients will 
enter the iPD range but it would speculative as to when they might fulfil diagnostic
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criteria. Another three patients have similar uptake and duration of illness to iPD 
patients but failed to fulfil diagnostic criteria for iPD. It is likely that other signs 
(mainly bradykinesia) will emerge soon which would then fulfil diagnostic criteria. 
Similar results was obtained in the asymptomatic basal ganglia in the 3 patients who 
had putamen uptake in the iPD range and 4 who had reduced uptake but above the 
iPD range. All H&Y I patients had abnormal uptake, thus confirming the ability of
I-FP-CIT SPECT in detecting the presymptomatic phase. Although this study was 
not designed to estimate the length of the presymptomatic stage, the abnormal uptake 
values above the parkinsonian range may hint at a relatively short presymptomatic 
stage.
Deuschl and Krack (1998b) proposed criteria to label patients with mainly resting 
tremor as mono-symptomatic resting tremor. Their criteria included pure or 
predominant resting tremor; no signs of bradykinesia, rigidity, or problems with 
stability of stance sufficient to diagnose iPD; and duration of tremor at least 2 years. 
The clinical features of patients 2 and 4 fulfil this criteria, and their striatal uptake is 
between normal and the established parkinsonian range. Also, patients 7 and 8 fulfil 
the mono-symptomatic resting tremor criteria but their striatal uptake is within the 
parkinsonian range. This adds to available evidence that some patients who exhibit 
only tremor have a dopaminergic deficit insufficient to produce other parkinsonian 
symptoms and signs. Probably the proposed title (mono-symptomatic resting tremor) 
represents patients with benign tremulous parkinsonism, but it is useful in 
emphasising that tremor need not always be associated with measurable bradykinesia.
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It is important to point out that abnormal 123I-FP-CIT SPECT indicates striatal 
degeneration and it is not diagnostic of iPD therefore patients with an abnormal scan 
could still have an early MSA or PSP. However resting tremor is less likely to be the 
key presenting feature in patients with MSA or PSP (Collins et al 1995a, Albanese et 
al 1995, Wenning et al 1997), making iPD the most likely diagnosis in 7 of our 10 
cases (cases 1-5, 7 and 8). We intend to review the clinical progress in these patients 
at one and two years to confirm the expected emergence of parkinsonian features and 
to repeat SPECT at two years to examine progression rates both clinically and by 
functional imaging.
Recently, Lee et al (1999), using 123I-IPT SPECT to assess the dopamine transporter 
compared 6 patients with isolated postural tremor (mean duration 16 years) with 6 
patients with postural and rest tremor (mean duration 18 years). They found no 
differences between uptake ratios of patients with isolated postural tremor and 
controls but uptake ratios were significantly lower in patients with postural and 
resting tremor than controls. However, uptake ratios in patients with postural and 
resting tremor were significantly higher than uptake ratios in iPD patients. Although 
their patients have a longer duration of tremor they exhibited little rigidity or 
bradykinesia, so they concluded that patients with long-standing postural tremor may 
develop resting tremor in association with mild nigral neuronal loss. Their findings 
are contrary to the findings of normal substantia nigra in postmortem studies of 
patients with postural and rest tremor (Rajput et al 1991b) and 18F-dopa SPECT
reports (Brooks et al 1992b). Lee et al (1999) argued that Rajput et al (1991b) did not
1 8count the number of nigral cells and F-dopa SPECT can be influenced by aromatic 
amino acid decarboxylase hyperactivity compensating for nigral neuronal loss. Our
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study did not address this issue. However, patient 10 in our study has had unilateral 
mild postural and resting tremor for 20 years and his 123I-FP-CIT SPECT showed 
normal uptake, indicating that longstanding tremor of this type can occur with a 
normal dopamine transporter system.
The present study examines the area of greatest immediate potential clinical 
application for basal ganglia imaging with 123I-FP-CIT. The results are encouraging 
for valid clinical use. Patients positively identified as having a dopaminergic deficit 
will have clinical suspicion of parkinsonism increased, while patients with a normal 
dopaminergic system are identified as more definitely non-parkinsonian. A minority 
of patients have been identified in this study, with intermediate readings between the 
range for established iPD and that for healthy volunteers. This rises the need for 
following-up research studies as mentioned above, and may indicate a need in 
selected cases for repeated basal ganglia imaging studies to determine whether 
progression has occurred. It will be important to establish whether, in this small 
subgroup of patients, repeat imaging provides useful data adding to repeat clinical 
observations.
6.5 CONCLUSIONS
1- 123I-FP-CIT showed reduced uptake in patients with resting tremor but not fulfilling 
standard diagnostic criteria confirming nigrostriatal degeneration, while excluding 
dopaminergic terminal damage in patients with isolated postural tremor.
2- Our findings indicate that 123I-FP-CIT could help in clarifying the diagnosis in 
patients with early or non-progressive tremor.
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3- This study confirms the existence of a presymptomatic phase in iPD. A larger 
sample of patients with repeated clinical and SPECT assessment in one and two years’ 
time is indicated to address the issues of disease progression and the length of the 
presymptomatic phase.
4- Further studies are needed to clarify the nigrostriatal changes in patients with 
longstanding postural tremor who develop resting tremor.
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CHAPTER 7 
STUDY 4
THE RELA TIONSHIP BETWEEN TREMOR 
DISORDERS, PARKINSONISM AND 
CEREBROVASCULAR DISEASE
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7.1 INTRODUCTION
Since it was introduced by Critchley in 1929, the concept of parkinsonism caused by 
or associated with cerebrovascular disease has been extensively debated and several 
alternative terms have been used including vascular parkinsonism, lower body 
parkinsonism, and arteriosclerotic pseudoparkinsonism. However, there are no 
generally accepted clinical criteria to diagnose the condition.
Hughes et al (1992) reported, in a clinico-pathological study of 100 cases with a 
clinical diagnosis of iPD, 3 patients with lacunar infarcts and no Lewy bodies, and 19 
iPD cases with co-existent striatal vascular pathology. This postmortem study 
provides evidence that iPD patients may also have cerebrovascular disease, and that 
patients with parkinsonism may have cerebrovascular disease but no pathological 
features of iPD (see chapter 1, page 19-23, for more detailed discussions of the issues 
relating to vascular parkinsonism).
Tremor is a rare manifestation of stroke, with only one patient reported to have tremor 
in a study of 2500 patients with first-ever stroke in Lausanne (Ghika-Schmid et al 
1997) and only three patients reported to have tremor in a review of 240 published 
cases of focal lesions affecting basal ganglia, two of whom had stroke (Bhatia and 
Marsden 1994). Tremor as a result of stroke usually accompanies other neurological 
features (Ferbert and Gerwig 1993, Kim 1992, Dethy et al 1993, Kim and Lee 1994, 
Qureshi et al 1996, Schulze-Bonhage and Ferbert 1998), but cases with isolated 
tremor as a result of stroke have been reported twice in the English literature (Lee et 
al 1993, McAuley et al 1998). An index case of isolated tremor due to cerebrovascular 
disease is described in this study.
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No previous PET or SPECT study has addressed the issue of vascular parkinsonism. 
The aim of this pilot study is to examine the changes in the basal ganglia in this group
1 9^of patients using I-FP-CIT SPECT, and to explore the concept of vascular
\,
\ parkinsonism.
7.2 METHODS
7.2.1 Study Subjects
Twelve patients of either sex, within an range between age 40-85 years, and with 
vascular parkinsonism defined as the presence of any cardinal feature of parkinsonism 
(bradykinesia, rigidity or tremor) and a clinical vascular risk factor profile and/or with 
subcortical ischaemic changes in structural neuroimaging (CT or MRI Scan) were 
selected from patients attending the movement disorder clinic. They were compared to 
6 healthy volunteers recruited from the previous study (Chapter 4).
Patients with clinical features suggestive of MSA or PSP were excluded and any drug
19^intake with the potential to interact with striatal uptake of I-FP-CIT by the 
dopamine transporter was disallowed, as discussed in the previous study (Chapter 4).
The( c]inical features and investigations of an index patient with isolated tremor 
attributed to stroke are described.
7.2.2 Study Assessments
Patients gave written informed consent and the study was approved by the Ethics 
Committee in Southern General Hospital and by the Administration of Radioactive 
Substances Advisory Committee. Standard safety assessments (vital signs, physical
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examination, laboratory tests) were conducted at baseline and repeated at least twice 
during the study period. Patients assessed using UPDRS motor section. The structural 
images were assessed by a Neuroradiologist blinded to the clinical data.
7.2.3 Imaging
The patients underwent the similar imaging procedures as described in the methods 
section in study 2 (Chapter 5).
7.2.4 Data Analysis
1 7^Visual assessment of I-FP-CIT SPECT consisted of institutional read only; a 
consensus blinded read was not performed. The SPECT scans were graded as normal 
and abnormal, which was graded further to abnormal grade 1, abnormal grade 2, and 
abnormal grade 3 (for full detailed definition see the method section of the study 1, 
chapter 4). Striatal specific:nonspecific uptake ratios analysis was performed 
according to the methods described in study 2 (Chapter 5).
7.2.5 Statistical Analysis
Comparisons of striatal uptake in vascular parkinsonism and healthy volunteers were 
made by one-way analysis of variance with Bonferroni correction for pre-specified 
multiple comparisons.
7.2.6 Index case
An index case of isolated tremor related to ischaemic stroke was studied in detail by 
repeated cranial imaging and neurophysiology testing, to explore the link between 
tremor conditions and structural cerebrovascular changes.
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7.3 RESULTS
Twelve patients with VP, (8 male, 67%), mean age 68 years (SD 8.2) and with median 
UPDRS motor score of 21 (interquartile range 8-34 (mean 15, SD 15) and 6 healthy 
volunteers, (4 male, 67%) mean age 63 years (SD 6.1) were recruited. For a detailed 
analysis of the clinical features of patients with vascular parkinsonism, see Table 7.1.
Of these 12 cases, 11 were abnormal. Eight of these had abnormalities which 
corresponded with the predefined grades (Table 7.2, Figure 7.1, 7.3). Three patients 
(cases 5, 6 and 11) had an unusual uptake pattern not conforming to the pre-defined 
grades, therefore their SPECT scans were not graded (figure 7.2). Only one patient 
(case 11) had a normal scan.
Specific:nonspecific ratios for both right and left caudate and putamen were 
significantly lower than in healthy volunteers (Table 7.3, Figure 7.4).
Index case
A 45 year-old right handed woman with sudden onset of tremor while walking which 
was initially fluctuant in the left thumb but then spread to all the digits of her left hand 
and became persistent. The tremor worsened with stress and excitement. There was no 
family history of tremor, or use of tremor-inducing drugs. She smoked 15 cigarettes 
per day and drank less than 2 units of alcohol per week. Initial assessment revealed a 
coarse mainly postural tremor affecting the left hand with no evidence of bradykinesia 
or rigidity. Limb reflexes were abnormally brisk in left arm and leg, otherwise the 
neurological examination was unremarkable. T2-weighted MRI revealed a small focal 
lesion in the anterolateral aspect of the right putamen and adjacent white matter
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considered most likely to be an ischaemic lesion (Figure 7.5 A). Her tremor failed to 
respond to propranolol, theophylline, and benzhexol. A year later she was treated with 
levodopa with no benefit. Two years later, with no improvement in her tremor, the 
MRI scan was repeated and showed no change in the lesion size (Figure 7.5 B). 
Further investigations including cerebrospinal fluid analysis and visual evoked 
potentials were normal, making demyelination improbable. Laboratory tests, 
including full blood count, ESR, coagulation screen, thrombophilia screen, 
autoantibody screen, syphilis serology, ureaJ electrolytes, creatinine, fasting glucose, 
liver function tests, calcium, phosphate, thyroid function test, serum and 24 hour 
urinary copper were all unremarkable. At that time, she reported that 2 units of 
alcohol were helpful in controlling her tremor. Five years after the onset there was no 
change in her tremor, which continues to be unilateral involving the left side. 
Although mild at rest, it worsens with changes in posture and now requires 4-5 units 
of alcohol to control it. On one occasion smoking cannabis produced a similar 
relieving effect as alcohol. Electrophysiological studies of her tremor were carried out 
by obtaining surface electromyography (EMG) recording from extensor digitorum 
communis and accelerometer recordings from the left middle finger. Recordings were 
made at rest and with her arm out-stretched. These revealed a 5-6 Hz tremor, which 
did not vary in frequency with posture. Frequency analysis of filtered rectified EMG 
also confirmed a dominant frequency of 5-6 Hz with additional harmonic activity seen 
at 11 Hz (Figure 7.6). She did not tolerate primidone; however her tremor improved 
with a single oral dose of 8mg ondansetron.
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Table 7.2 123I-FP-CIT institutional read results for vascular parkinsonism and healthy
volunteers.
Normal Abnormal
Grade 1 Grade 2 Grade 3
Vascular parkinsonism 
(n=12)*
1 2 5 1
Healthy volunteers 
(n=6)
6 0 0 0
*3 patients (cases 5, 7 and 10) had an unusual uptake pattern, therefore their 
SPECT was not included in the grading.
Normal (grade 0): Symmetrical uptake in both right and left caudate and putamen. 
Abnormal (grade 1): Uptake is symmetrical with almost normal or reduced putamen 
activity in one hemisphere and a more marked change on the other side.
Abnormal (grade 2): Uptake is significantly reduced in the putamen on both the right 
and left sides.
Abnormal (grade 3): Uptake is virtually absent from both putamen and caudate nuclei 
on each side.
For more detailed definition o f abnormal scan types, see methods section in study 1, 
chapter 4.
169
Table 7.3 A) Striatal 123I-FP-CIT specific:nonspecific uptake ratios of patients with
vascular parkinsonism (12) and healthy volunteers (6).
Right Left Right Left
caudate caudate putamen putamen
Vascular 2.2* 2.6** 1.4A 1.8*
parkinsonism (1.7, 2.7) (2.0, 3.1) (0.86, 2.0) (1.1, 2.4)
Healthy 3.5 3.5 3.1 3.1
volunteers (3.1,3.8) (3.1, 4.0) (3.0, 3.3) (2.8, 3.4)
* p<0.01 compared to healthy volunteers 
** p<0.05 compared to healthy volunteers 
A p<0.001 compared to healthy volunteers
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Table 7.3 B) Specific rnonspecific 123I-FP-CIT uptake ratios in 12 patients with
vascular parkinsonism.
Patient
number
Caudate Putamen
Right Left Right Left
1 1.84 1.87 0.78 0.72
2 1.98 2.11 0.98 1.05
3 1.33 1.93 0.65 0.65
4 1.21 0.95 0.73 0.49
5 1.21 3.25 0.87 2.63
6 2.78 2.79 2.02 1.69
7 2.01 3.05 1.35 2.73
8 2.03 2.59 0.92 1.34
9 2.32 2.16 1.31 1.14
10 2.90 3.39 2.43 3.28
11 3.91 3.97 3.73 3.64
12 2.69 2.47 1.48 1.34
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Figure 7.1 Abnormal 123I-FP-CIT uptake in patients with lower body parkinsonism
(cases 1 and 2).
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Figure 7.2 Structural and functional imaging in case 5
A) CT scan showing 3 lacunar infarctions in the right basal ganglia (arrows)
B) Severe reduction in 123I-FP-CIT uptake in left striatum with almost normal 
appearance on the other side.
C) IBZM SPECT showing severe reduction in the uptake ratios.
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Figure 7.3 Structural and functional imaging in case 6
A) CT scan showing a lacunar infarct in left putamen (arrows).
B) Abnormal 123I-FP-CIT uptake in the bilateral striatum (grade 1).
176
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Figure 7.4 Striatal specific:nonspecific ratios in patients with vascular parkinsonism
(12) and healthy volunteers (6).
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Figure 7.5: A) T2-weighted MRI, 6 months after acute onset of left arm tremor, 
shows an ischaemic lesion in anterolateral aspect of the right putamen (arrow). 
B) Repeat MRI at 30 months shows no change (arrow).
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Figure 7.6: A) Surface recording EMG from left extensor digitorum communis which 
shows a regular 5-6 Hz tremor with arm out-stretched.
B) Simultaneous accelerometer recording from the left middle finger also 
demonstrating 5-6 Hz tremor.
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7.4 DISCUSSION
The principal finding in the present study is of an abnormality in the dopaminergic 
neurones in patients with parkinsonism and vascular risk factors. This result, together 
with previous clinical, postmortem and structural imaging studies in such patients 
(Hughes et al 1990, Zijlmans et al 1995, Winikates and Jankovic 1999), indicates a 
basal ganglia origin for the clinical parkinsonian features in such cases and suggests 
that the label “pseudoparkinsonism” is no longer appropriate. Cerebrovascular 
parkinsonism should therefore be regarded as a parkinson’s variant, which may have 
clinical features distinguishing it from iPD, and which is typified (like other 
parkinsonian variants such as MSA and PSP) by a limited levodopa response.
Given the variability of cerebrovascular disease reported in the literature in 
association with parkinsonism and iPD itself, it is appropriate to review clinical and 
imaging data in the cases studied. Cases 1 and 2 presented with generally accepted 
features of VP (difficulty in gait initiation, older age, hypertension, short duration of 
disease, lower more than upper body features, symmetrical disease and poor response 
to levodopa) making iPD very unlikely (Winikates and Jonkovic 1999). It is 
interesting that both of these patients have a short duration of illness (less than 18 
months) and mild to moderate disease severity (UPDRS 22 and 9 respectively) but 
123I-FP-CIT uptake was severely reduced (both grade 2 in the visual assessment with 
low SP:NS ratios) indicating severe degeneration in the dopaminergic terminals. In 
study 2 (Chapter 5) it has been shown that striatal ,23I-FP-CIT uptake correlates with 
disease severity and duration in iPD. The degree of loss of dopamine transporters in 
these two VP cases is greater than expected from their disease severity and duration- 
by approximately 45%. Thus ischaemia may be associated with an accelerated rate of
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basal ganglia degeneration than iPD leading to a more severe drop in the number of 
dopamine transporters.
An insidious onset of parkinsonism due to lacunar infarction producing clinical 
features similar in all aspects to iPD including a response to levodopa has been 
described, and is supported by postmortem studies (Tolosa and Santamaria 1984, 
Murrow et al 1990, Hughes et al 1991, 1992, Inzelberg et al 1994, Reider-Groswasser 
et al 1995, Mark et al 1995). Case 3 may be in such a diagnostic sub-group with an 8 
year history of parkinsonism which presented with unilateral tremor and progressed to 
bradykinesia and rigidity, and a good response to levodopa. The possibility of co­
existent iPD and cerebrovascular disease is raised. Cases 4, 8, 9 and 12, presented 
with similar features with exception of a poor response to levodopa. It is interesting to 
speculate whether the dominance of vascular over idiopathic Parkinson’s disease 
determines the degree of levodopa response in individual cases.
Cases 5 and 10, who present with a hypokinetic-rigid syndrome and no tremor, 
showed a reduction in the SP:NS ratios in the right striatum but a almost normal 
SP:NS ratio in the left striatum. This pattern is not typical of iPD and it matches the 
structural changes seen on CT scan, namely right basal ganglia lacunar infarction and 
no ischaemic lesions in the contralateral striatum. The compatibility between 
structural and functional imaging indicates that this is a further type of vascular 
parkinsonism, easily distinguishable from lower body parkinsonism. However, the 
onset of parkinsonism in our patient was delayed for years after the initial clinical 
stroke event and this differs from other reports of patients with acute parkinsonian 
features within one month of the ischaemic event (Friedman et al 1986, Mayo et al
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1986, Winikates and Jankovic 1999). The likely explanation is that this patient had 
several subclinical strokes leading eventually to the development of parkinsonism. 
The clinical features and the pattern of dopamine transporter loss make the diagnosis 
of iPD extremely unlikely. Further, a reduction in D2 IBZM uptake ratios in case 5 
compatible with atypical parkinsonism and contrary to the normal or increased uptake 
in iPD patients was found (Schwarz et al 1993, van Royen et al 1993, Arnold et al 
1994). Generally patients with VP do not respond to levodopa (FitzGerald and 
Jankovic 1989, Winikates and Jankovic 1999) and this is attributable to a reduction in 
post-synaptic dopamine receptors.
Lee et al (1993) reported a patient with a sudden onset of right hand, levodopa 
responsive resting tremor without other features of parkinsonism. MRI revealed a 
lacunar infarct at the border between the left thalamus and the internal capsule. The 
thalamic lesion was thought to be the cause of the tremor but the possibility of early 
Parkinson’s disease could not be excluded. In contrast the tremor in the index case is 
of a higher frequency and did not respond to levodopa, and rigidity and bradykinesia 
are absent after 5 years follow-up, thus excluding iPD. Recently McAuley et al (1998) 
reported a patient with a sudden onset of right hand and arm tremor present at rest, 
and also present with posture and movement. The tremor was unresponsive to 
primidone, did not change in severity after 2 years, and was initially labelled 
psychogenic. However, electrophysiological studies revealed 7-8 Hz polyphasic 
bursts and MRI showed a small ischaemic lesion in the left lentiform nucleus. They 
concluded that the tremor resulted from the ischaemic lesion. The index patient has 
some clinical similarity to this case. However some of the tremor features in the index 
patient are suggestive of midbrain tremor: being present at rest and worsening with
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posture and movement (Berkovic et al 1984, Hpfensperger et al 1995) but the higher 
frequency, lack of other neurological signs and site of the ischaemic lesion on MRI 
are against this. Also, her tremor frequency is in the ET range and shows a definite 
response to alcohol. However its presence at rest, with a sudden onset, and lack of 
later progression, indicates that she fails established diagnostic criteria for both iPD 
and for ET. Thus the index case of isolated tremor is likely to represent a 
manifestation of stroke. Case 6 also presented with isolated tremor with no other 
features of parkinsonism for more than 18 months and his CT showed an ischaemic 
lesion in the corresponding putamen making the diagnosis of isolated tremor due to
1 91stroke a possible explanation. However, his bilateral reduction in striatal I-FP-CIT 
uptake would be compatible with a diagnosis of iPD although he did not exhibit 
features such as rigidity and bradykinesia to support this. The likelihood may be of 
co-existent iPD and cerebrovascular disease, with the ischaemic lesion in the basal 
ganglia accelerating the presentation of the tremor.
Only one of the 12 patients (case 11) in the vascular group, with unilateral tremor for 
14 years, had normal striatal 123I-FP-CIT uptake. The clinical features of the tremor, 
its duration and the appearance of the SPECT scan are against the diagnosis of 
parkinsonism. Also, it is unlikely to be ET or related to the ischaemic lesions. Case 7 
presented with right sided tremor, but both structural and I-FP-CIT imaging showed 
abnormalities in the right basal ganglia which cannot explain his clinical features. A 
long-term clinical and imaging follow-up may be the only way to clarify the nature of 
the tremor in these patients.
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The findings in the present study of preganglionic dopamine loss in cases of 
cerebrovascular lesions with parkinsonian features need to be examined in light of the 
varying mechanisms suggested for this disorder. Ischaemic basal ganglia lesions or 
white matter lesions disrupting the sensorimotor integration have been suggested 
(Tolosa and Santamaria 1984, Mayo et al 1986, Murrow et al 1990, Reider- 
Groswasser et al 1995, Zijlmans et al 1995 Baloh and Vinters 1995, Baloh et al 1995). 
The gait disorder in Binswanger’s disease was attributed to diffuse vascular lesions 
disrupting basal ganglia-motor cortex connections (Thompson and Marsden 1987) and 
Winikates and Jankovic (1999) proposed a similar mechanism for VP. Our study 
suggested that both of these purported mechanisms occur: in striatal infarction pre- 
synaptic dopamine neurones are directly affected, but these abnormalities also occur 
in patients without white matter changes.
We deliberately included cases with variations in vascular risk factors, structural 
imaging, and levodopa responsiveness in this study, because of the persisting 
uncertainty of an association between cerebrovascular disease and parkinsonism. Our 
study justifies the concept of vascular parkinsonism and shows two patterns of 
dopaminergic loss which differ from iPD, namely significant symmetry in cases of 
lower body parkinsonism, and an asymmetric loss at the site of focal infarction seen 
on structural imaging. Further evaluation of vascular parkinsonism with preganglionic 
dopamine transporter imaging to examine clinical, structural imaging, and therapy 
response, is justified by the present novel and significant results. Also, postmortem 
data would be helpful in this category of patients, to define the presence of Lewy 
bodies. However prior postmortem studies have already found an overlap between
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Lewy bodies and cerebrovascular disease, as well as Lewy body negative vascular 
parkinsonism (Hughes et al 1992).
7.5 CONCLUSION
1- This study shows that striatal 123I-FP-CIT uptake differentiates VP from healthy 
volunteers.
2- This is the first functional neuroimaging study in VP patients and supports the 
concept of vascular parkinsonism by showing striatal degeneration, indicating that 
disruption of the dopaminergic nerve terminals by vascular lesions is a possible 
mechanism for producing parkinsonian symptoms and signs.
3- Our study showed two patterns of dopaminergic loss in VP which differ from iPD 
namely a significantly symmetric pattern in cases of lower body parkinsonism, and an 
asymmetric loss at the site of focal infarction seen on structural imaging.
4- This exploratory study suggests heterogeneity in patients with vascular 
parkinsonism and justifies a larger sample to examine clinical and therapy correlates 
with preganglionic dopamine transporters in more detail.
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